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SUMMARY 
INTRODUZIONE:  
Il cancro all’ovaio viene considerato un tumore resistente alla terapia e questa farmaco-
resistenza si pensa sia correlata alla presenza delle cellule staminali tumorali (CSC). Le cellule 
staminali tumorali sono una rara e piccola popolazione cellulare responsabile dell’insorgenza 
del tumore, del mantenimento della sua crescita, dei casi di recidive e metastasi, in seguito 
alla loro proprietà di farmaco-resistenza. Considerando queste premesse, è indispensabile 
caratterizzare queste cellule in modo da trovare un possibile bersaglio terapeutico e 
migliorare i risultati delle terapie attuali. 
Le cellule tumorali sono caratterizzate da un metabolismo altamente glicolitico anche in 
presenza di ossigeno, denominato “Effetto Warburg”. Poco si conosce riguardo al 
metabolismo delle cellule staminali tumorali, e soprattutto non è noto se l’effetto Warburg è 
una condizione condivisa. 
Questo progetto di ricerca si prefigge di: 
- caratterizzare le CSC nel campioni primari di liquido ascitico di cancro all’ovaio; 
- studiare il profilo metabolico delle CSC isolate, per identificare eventuali differenze 
con la controparte differenziata.  
 
RISULTATI: 
Inizialmente abbiamo identificato le CSC, secondo la co-espressione dei marcatori CD44 (il 
recettore dell’acido ialuronico), e CD117 [c-kit, recettore della citochina SCF (Stem Cell 
Factor)] in 40 campioni di liquido ascitico di cancro all’ovaio di pazienti in cura all’ospedale di 
Padova. Questa rara popolazione cellulare CD44+CD117+ è in grado di formare strutture 
sferoidali; è altamente tumorigenica in topi immunodeficienti; presenta farmaco-resistenza, 
dimostrata con trattamenti in vitro con farmaci solitamente utilizzati in clinica; ed è 
caratterizzata da un’alta espressione di geni codificanti: pathway di staminalità (Nanog, 
Oct4, Sox2), pompe o enzimi detossificanti, coinvolti nei fenomeni di farmaco-resistenza 
(ABCG2, MRP1, MRP2 e ALDH1A) e enzimi coinvolti nel fenomeno della transizione epitelio-
mesenchimale, importante nei processi di metastasi (SNAIL1, SNAIL2, ZEB1, ZEB2, TWIST1). 
Complessivamente, questi risultati dimostrano che le cellule CD44+CD117+ rappresentano 
una popolazione con caratteristiche di staminalità. 
A seguito di questa caratterizzazione fenotipica, abbiamo studiato il profilo metabolico delle 
cellule CD44+CD117+, confrontandolo con quello della controparte non-staminale 
(CD44+CD117-). In primo luogo, abbiamo esaminato l’espressione di geni coinvolti in diverse 
importanti vie metaboliche, tra cui: il metabolismo del glucosio, il ciclo dell'acido 
tricarbossilico (TCA), la catena di trasporto degli elettroni (ETC) nel processo della 
respirazione mitocondriale, la via dei pentoso fosfati (PPP), e la β-ossidazione degli acidi 
grassi. 
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Le cellule CD44+CD117+ mostrano alti livelli di espressione dei geni associati alla glicolisi, e 
sono caratterizzate da una forte dipendenza dalla via dei pentoso fosfati e della β-
ossidazione degli acidi grassi, dimostrata da una significativa diminuzione della loro vitalità in 
seguito a trattamento in vitro con due inibitori specifici delle due vie metaboliche (DHEA e 
Etomoxir rispettivamente).  
Inoltre le cellule CD44+CD117+ sono caratterizzate da un'alta espressione dei geni codificati 
enzimi coinvolti nel ciclo di Krebs e  nella fosforilazione ossidativa (OXPHOS). Questo 
risultato ci ha permesso di analizzare l'espressione di un enzima chiave del ciclo di Krebs, la 
piruvato deidrogenasi (PDH), fondamentale nel trasporto del piruvato dalla glicolisi alla 
respirazione cellulare. Abbiamo verificato livelli di espressione comparabili dell’enzima PDH 
nelle due popolazioni cellulari CD44+CD117+ e CD44+CD117-, mentre l’enzima PDHK1, che 
inattiva la piruvato deidrogenasi tramite fosforilazione, risulta meno espressa nella 
popolazione CD44+CD117+. Questi dati suggeriscono che nelle cellule staminali tumorali 
venga privilegiato il trasporto del piruvato verso i mitocondri, per catalizzare il metabolismo 
della respirazione mitocondriale. 
Alla luce di questi risultati, abbiamo studiato l’attività mitocondriale nella popolazione 
staminale e nella controparte non staminale. In particolare le cellule CD44+CD117+ sono 
caratterizzate da bassi livelli di ROS (specie reattive dell’ossigeno) totali, da alti livelli di ROS 
mitocondriali, da una iper-polarizzazione del potenziale di membrana mitocondriale in 
seguito a trattamento con oligomicina (inibitore dell’ATP-sintasi) e da una drammatica 
diminuzione della vitalità cellulare in seguito a trattamento con inibitori specifici della catena 
di trasporto degli elettroni (ETC) (oligomicina inibitore dell’ATP-sintasi; rotenone inibitore 
del complesso I e antimicina inibitore del complesso III). 
 
Complessivamente, questi risultati ci hanno suggerito un modello sperimentale del profilo 
metabolico delle cellule staminali tumorali CD44+CD117+, le quali privilegiano la via della 
respirazione mitocondriale, a discapito della via glicolitica.  
 
Inoltre, abbiamo dimostrato che un trattamento in vitro e in vivo (2DG) di deprivazione di 
glucosio o blocco della via glicolitica seleziona una popolazione di cellule con caratteristiche 
di staminalità: incremento dell’espressione dei marcatori CD44 e CD117, farmaco-resistenza, 
tumorigenicità in vivo, formazion dii sferoidi in vitro ed espressione di geni convolti in 
pathway tipici delle cellule staminali. Questa popolazione cellulare ha mostrato una down-
regolazione della maggior parte delle vie metaboliche, entrando in uno stato di quiescenza 
pur mantenendo livelli di espressione significativi dei geni codificanti enzimi del 
metabolismo ossidativo e iper-polarizzazione del potenziale di membrana mitocondriale,  
nonché dell’attività dei  mitocondri. 
 
 
~ 5 ~ 
 
A conclusione del progetto e come ulteriore dimostrazione del profilo metabolico ossidativo 
delle cellule staminali tumorali, contrario all’effetto Warburg sfruttato dalle cellule tumorali, 
abbiamo eseguito degli esperimenti in vitro con due farmaci che colpiscono le vie 
metaboliche della respirazione cellulare: Metformina e CPI-613. Metformina inibisce il 
complesso I della catena di trasporto degli elettroni ed è attualmente in uso in studi clinici 
come farmaco antitumorale promettente; CPI-613 è un farmaco innovativo che inibisce due 
enzimi chiave del ciclo degli acidi tricarbossilici, PDH e α-KGH. Trattamenti in vitro con questi 
farmaci hanno dimostrato una significativa diminuzione della vitalità delle cellule 
CD44+CD117+, fondamentale verifica della loro dipendenza da questo profilo metabolico. 
 
CONCLUSIONI: 
In questo studio abbiamo investigato il profilo metabolico delle cellule staminali tumorali, 
isolate ex-vivo da campioni di liquidi ascitici di pazienti con carcinoma ovarico, dimostrando 
che le CSC ovariche, a differenza delle cellule differenziate neoplastiche, sfuggono all’effetto 
Warburg, utilizzando preferibilmente una respirazione ossidativa. 
Questa osservazione può indicare nuove strade e nuove strategie per approcci di  terapie  
mirate nei confronti delle CSC, alla luce delle peculiari caratteristiche del loro metabolismo. 
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ABSTRACT 
Ovarian cancer is the fourth leading cause of cancer-related death in women and the leading 
cause of gynecologic cancer death. Moreover, it is regarded as a therapy resistant tumor, 
because it shows the formation of more aggressive recurrence of the primary tumor as a 
result of chemotherapy. This chemo-resistance is thought to be related to the presence of 
the Cancer Stem Cells (CSC). Tumor cells are characterized by a high glycolytic metabolism 
even in the presence of oxygen, the so-called Warburg effect; however, it is unclear whether 
this condition is also shared by CSC. 
 
We identified ovarian CSC, according to their co-expression of CD44 and CD117 markers, in 
40 samples of ascitic effusions from ovarian cancer-bearing patients. We have analyzed 
phenotipic characteristics by investigating stemness marker expression by flow-cytometry, 
spheroid formation assay, tumorigenicity in vivo and gene expression in RT-PCR. For the 
analysis of metabolic characteristics, ovarian cancer cells were FACS-sorted  in to 
CD44+CD117+ and CD44+CD117- cell populations and analyzed through specific metabolic 
gene-cards. Results were confirmed also through Western Blot for specific metabolic 
enzymes and functional assay of mitochondrial activity. 
 
We have demonstrated that CD44+CD117+ EOC cells presented high tumorigenicity and 
expressed stemness-associated markers and multidrug resistance pumps. 
Moreover, the CD44+CD117+ cell population overexpressed genes associated with glucose 
uptake, oxidative phosphorylation (OXPHOS), and fatty acid -oxidation, indicating higher 
ability to direct pyruvate towards the Krebs cycle. Consistent with a metabolic profile 
dominated by OXPHOS, the CD44+CD117+ cells showed higher mitochondrial reactive oxygen 
species (ROS) production and elevated membrane potential, and underwent apoptosis upon 
inhibition of the mitochondrial respiratory chain. The CSC also had a high rate of pentose 
phosphate pathway (PPP) activity, which is not typical of cells privileging OXPHOS over 
glycolysis, and may rather reflect the PPP role in recharging scavenging enzymes. 
Furthermore, CSC resisted in vitro and in vivo glucose deprivation, while maintaining their 
CSC phenotype and OXPHOS profile. 
In this study, we show that a subpopulation of CD44+CD117+ EOC cells fulfilling the canonical 
properties of CSC does not preferentially exploit a glycolytic metabolism, privileging instead 
the mitochondrial respiratory pathway. These observations could explain the CSC resistance 
to anti-angiogenic therapies, and indicate this peculiar metabolic profile as a possible target 
of novel treatment strategies. 
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1. INTRODUCTION 
 
Cancer is a term used for diseases in which abnormal cells divide without control and are 
able to invade other tissues, through the blood and lymph systems. Cancer is the leading 
cause of death in economically developed countries, and the second cause of death in 
developing countries. 
 
Cancer starts when cells in a part of the body start to grow out of control. Instead of dying, 
cancer cells continue to grow and form new, abnormal cells. Therefore, all cancers involve  
the malfunction of genes that control cell growth and division. Some cancers are strongly 
hereditary, but most cancers result from damage to genes occurring during a person’s 
lifetime. Genetic damage may result from both intrinsic factors (inherited mutations, 
hormones, immune conditions and mutations that occur from metabolism) or extrinsic 
factors (such as tobacco smoke, infectious organisms, chemicals and radiations).  
 
The traditional approaches designed to remove or kill rapidly-dividing cancer cells are 
surgery, radiation therapy and systemic treatments such as chemotherapy or hormonal 
therapy. It has been shown that all these methods have limitations in clinical use, because 
some types of cancer, like ovarian cancer, are characterized by high recurrence [1]. 
 
The idea is that this recurrence could be related to the presence of a rare cell population, 
characterized by stemness properties, called Cancer Stem Cells (CSC).  
 
1.1 Anatomy of ovary and ovarian cancer 
 
The ovaries, a pair of tiny glands in the female pelvic cavity, are the most important organs 
of the female reproductive system. Their importance relies on their role in producing both 
the female sex hormones that control reproduction and the female gametes that are 
fertilized to form embryos. 
Each ovary is a small glandular organ of about the shape and size of an almond. The ovaries 
are located on opposite sides of the uterus in the pelvic cavity and are attached to the uterus 
by the ovarian ligament. Several paired ligaments support the ovaries. The ovarian ligament 
connects the uterus and ovary. The posterior portion of the broad ligament forms the 
mesovarium, which supports the ovary and houses its arterial and venous supply. The 
suspensory ligament of the ovary (infundibular pelvic ligament) attaches the ovary to the 
pelvic sidewall (Figure 1). This larger structure also contains the ovarian artery and vein, as 
well as nerve supply to the ovary.  
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Figure 1: Anatomy of ovary. Animated Dissection of Anatomy for Medicine (A.D.A.M.)  
(www.adameducation.com) and Human anatomy and Physiology by Benjamin Cummings. 
The tissues of the ovaries are arranged into several distinct layers: 
 A most external layer of simple epithelium, known as the germinal epithelium, forms 
a soft, smooth covering of the ovary. 
 The tunica albuginea is a thick band of tough fibrous connective tissue just below the 
germinal epithelium, which supports and protects the delicate underlying tissues.  
 Deep to the tunica albuginea is the ovarian cortex, which contains follicles and their 
supporting connective tissues. The follicles contain oocytes that mature into ova 
throughout a woman’s reproductive years. 
 The innermost layer, the ovarian medulla, contains most of the vascular tissue that 
supports the other layers of the ovary. 
The ovaries play two central roles in the female reproductive system by acting as both glands 
and gonads. Acting as glands, the ovaries produce several female sex hormones including 
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estrogens and progesterone. Estrogen controls the development of the mammary glands 
and uterus during puberty and stimulates the development of the uterine lining during the 
menstrual cycle. Progesterone acts on the uterus during pregnancy to allow the embryo to 
implant and develop in the womb. 
The most important disorders of the ovaries are: ovarian cysts and ovarian cancer. Ovarian 
cysts are fluid-filled sacs that can form in the ovaries when either egg is not released or the 
follicle, a sac in which egg cells form, does not dissolve after the egg is released. Small 
ovarian cysts are common in healthy women, but some women have more follicles than 
usual (polycystic ovary syndrome), which inhibits the follicles to grow normally and this will 
cause cycle irregularities. Most cysts are not cancerous and will not become cancerous. In 
the past, surgery to remove cysts was the treatment of choice, but many studies showed 
that regular monitoring of the cyst, using ultrasound scan and blood tests, is possible for 
most women.  
The protein CA125 (cancer antigen 125) is normally analyzed in the blood of women affected 
by ovarian cysts, and high levels are indicative of ovarian cancer. Other chemicals analyzed 
to diagnose ovarian cancer are: lactate dehydrogenase (LDH), alpha feta protein (AFP) and 
human chorionic gonadotropin (HCG).  
Ovarian cancer is the seventh most common cancer in women (Figure 2) and the 18th most 
common cancer overall worldwide.  
 
Figure 2: Cancer occurrence in women. Ovarian cancer is the seventh most common cancer in women.  
Jemal A, Siegel R, Ward E et al. (2008). "Cancer statistics, 2008". CA Cancer J Clin (2):71-96. 
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SEER (Surveillance, Epidemiology and End Results – Program of the National Cancer Institute, 
which works to provide informations on cancer statistics) estimates that in 2014, about 
21.980 new cases of ovarian cancer are diagnosed and 14.270 women are died of ovarian 
cancer (Figure 3). A woman’s lifetime risk of developing invasive ovarian cancer is 1 in 72 and 
of dying from it is 1 in 100. 
 
Figure 3: Statistics of ovarian cancer – SEER analysis. National Cancer Institute 
(http://seer.cancer.gov/statfacts/html/ovary.html) 
 
 
Ovarian cancer rates are highest in women aged 55-64 years. Five-year survival rates are 
commonly used to compare different cancers and the relative survival rate for ovarian 
cancer is 44,6 percent. Survival rate varies greatly depending on the time of diagnosis, but 
approximately only 15 percent of ovarian cancer patients are diagnosed early with early 
stage disease. As a matter of fact, ovarian cancer is denominated “silent killer” [4, 5], 
because more than 80 percent of patients have symptoms, even when the disease is still 
limited to the ovaries. Moreover, the symptoms are shared with many more common 
gastrointestinal, genitourinary and gynecological diseases. 
The diagnosis can be formulated through the following methods: transvaginal sonography 
(TVS), serum markers, and a combination of the two modalities . 
Among the serum markers, the CA125 protein has received most attention, but greater 
specificity can be achieved by combining it and TVS. Data from a clinical trial, done in United 
Kingdom in 200.000 subjects, suggest that this strategy could increase the percentage of 
disease detection at early stages (48%) with adequate sensitivity (89,4%) and specificity 
(99,8%). 
 
Ovarian cancer has a distinctive biology and behavior at the clinical, cellular and molecular 
levels. 
Some factors and conditions may increase a woman's risk of developing this condition: 
 A family history of ovarian cancer: Women who have two or more close relatives 
with the disease have an increased risk of developing ovarian cancer. Certain genes, 
such as the BRCA 1 and 2 genes, are inherited and result in a high risk for 
development of ovarian cancer. 
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 A family history of breast or colon cancer also confers an increased risk for the 
development of ovarian cancer. 
 Childbearing and menstruation: nulliparous women have a greater risk of developing 
ovarian cancer compared to women who have had children. In fact, the number of 
childbirths correlates directly with a decrease in risk of developing ovarian cancer. 
The likely explanation for this risk factor seems to be related to the number of 
menstrual periods a women has had in her lifetime. Those who began menstruating 
early (before age 12), had no children, had their first child after age 30, and/or 
experienced menopause after age 50 have a greater chance of developing ovarian 
cancer than the general population. 
 Medications: Some studies showed that women who have taken fertility drugs, or 
hormone therapy after menopause, may have a slightly increased risk of developing 
ovarian cancer. The use of oral contraceptives, on the other hand, seems to decrease 
the chance of manifesting the disease. 
Most tumors of the ovary can be grouped into one of three major categories: epithelial-, sex 
cord-stromal-, and germ cell tumors, according to the anatomic structures from which the 
tumors presumably originate. Each category includes a number of subtypes. 
Epithelial ovarian carcinoma is the most frequent form (95% of all the tumors); based on 
histopathology and molecular genetic alterations, it is  divided into five main types: high-
grade serous (70%), endometrioid (10%), clear-cell (10%), mucinous (3%), and low-grade 
serous carcinomas (<5%). These types are essentially distinct diseases, as indicated by 
differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, 
and molecular events during oncogenesis, response to chemotherapy, and prognosis (Table 
1) [6]. For a successful specific treatment, reproducible histopathological diagnosis of the 
tumor cell type is critical. The five tumor types are morphologically diverse and resemble 
carcinomas of the uterus. Actually, recent investigations have demonstrated that a 
substantial number of cancers, traditionally thought to be primary ovarian tumors 
(particularly serous, endometrioid, and clear-cell carcinomas), originate in the Fallopian 
tubes and the endometrium and involve the ovary secondarily. Unfortunately the exactly 
origin of ovarian cancer is poorly understood and probably it is the cause of the failures of 
early detection and new therapeutic approaches to reduce mortality incidence [7]. 
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Table 1: Epithelial ovarian  carcinoma: clinical and molecular features of the five most common types. HGSC, 
high-grade serous carcinoma; LGSC, low-grade serous carcinoma; MC, mucinous carcinoma; EC, endometrioid 
carcinoma; CCC, clear-cell carcinoma. 
a
Hereditary nonpolyposis colorectal carcinoma. Lalwani N., Prasad S.R., 
Vikram R., Shanbhogue A.K., Huettner P.C., Fasih N. Histologic, Molecular, and Cytogenetic Features of Ovarian 
Cancers: Implications for Diagnosis and Treatment. RadioGraphics 2011;31:3.  
The International Federation of Gynecology and Obstetrics (FIGO) has classified ovarian 
carcinoma in four stages [8]: 
- Stage 1: tumor is confined to ovaries and Fallopian tubes; 
- Stage 2: tumor involves one or both ovaries or Fallopian tubes with pelvic extension or 
primary peritoneal cancer; 
- Stage 3: tumor involves one or both ovaries or Fallopian tubes, or primary peritoneal 
cancer, with cytologically or histologically confirmed spread to the peritoneum outside the 
pelvis and/or metastasis to the retroperitoneal lymph nodes; 
- Stage 4: distant metastasis excluding peritoneal 
metastases.  
Furthermore, one third of ovarian cancer patients 
present with ascites, a generally voluminous exudative 
fluid with a cellular fraction consisting mainly of ovarian 
cancer cells, lymphocytes, and mesothelial cells (Figure 
4). The neoplastic cells in the ascites are present either 
as single cells, as aggregates, or as spheroids, and may 
contribute to the spread of cancer to secondary sites [9]. 
 
 
Figure 4: Ovarian carcinoma ascitic fluid. Cancer Research UK (www.cancerresearchuk.org). 
 
Treatment usually relies on surgery and chemotherapy, sometimes in combination with 
radiotherapy, and is obviously more efficient when the disease is confined to the ovary. 
Chemotherapy include paclitaxel, cisplatin, topotecan and gemcitabine. Due to the lack of 
 HGSC LGSC MC EC CCC 
Risk factors BRCA1/2 ? ? HNPCC
a
 ? 
Precursor lesions Tubal 
intraepithelial 
carcinoma 
Serous 
borderline 
tumor 
Cystadenoma/borderline 
tumor? 
Atypical 
endometriosis 
Atypical 
endometriosis 
Pattern of spread Very early 
transcoelomic 
spread 
Transcoelomic 
spread 
Usually confined to 
ovary 
Usually 
confined to 
pelvis 
Usually 
confined to 
pelvis 
Molecular 
abnormalities 
BRCA, p53 BRAF, KRAS KRAS, HER2 PTEN, ARID1A HNF1, ARID1A 
Chemosensitivity High Intermediate Low High Low 
Prognosis Poor Intermediate Favorable Favorable Intermediate 
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effective screening programs, ovarian cancer is diagnosed at an early stage only in about 
20% of the cases. In most of these cases, surgery is able to cure the disease, and the five-
year survival rate for early-stage (stage I or II) ovarian cancer is around 90%. Instead the 
standard treatment for patients with advanced ovarian cancer is maximal surgical 
cytoreduction followed by systemic platinum-based chemotherapy and, actually, is 
reasonable to expect a 5-year survival for 10-30% of women diagnosed with ovarian cancer 
at stage 3 or 4. Despite the activity of first-line chemotherapy, which gives response rates up 
to 80% in first line treatment, the majority of patients due to  recurrencies. For this reason, 
ovarian carcinoma is considered a chemo-resistant cancer, and studying its biology to 
improve the therapies mandatory [10]. 
Many studies have demonstrated a correlation between the phenomenon of 
chemoresistance and the presence of a small and rare cellpopulation with characteristics of 
stemness, the Cancer Stem Cells [11]. 
 
1.2 Stem Cells and stemness 
 
Stem cells are the precursor of all cells in the human body and what makes stem cells special 
is their extreme “flexibility”. 
 
They are characterized by the following features: 
 
- Self-renewal: it is the process by which stem cells divide to make more stem cells, 
perpetuating the stem cell pool throughout life in a non-differentiate state. This requires a 
tight cell cycle control and often maintenance of multipotency or pluripotency, depending 
on the stem cell. Self-renewal programs involve networks that balance proto-oncogenes 
(promoting self-renewal), gate-keeping tumor suppressors (limiting self-renewal), and care-
taking tumor suppressors (maintaining genomic integrity). These cell-intrinsic mechanisms 
are regulated by cell-extrinsic signals from the “niche”, the microenvironment that maintains 
stem cells and regulates their function in tissues. 
 
- Potency: it is the potential to differentiate into different cell types. Stem cells can be: 
totipotent, when they are able to form all cell types in a body; pluripotent, when they create 
all cell types except for extra-embryonic tissues; multipotent, when they can differentiate 
into specific cell types, closely related to the tissue where they are localized. 
 
- Asymmetric division: it is the capacity to form, during cell division, two daughters cells, one 
identical to the original stem cell, and another differentiated. 
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- Ability to survive in stress condition: it includes the resistance to drugs and natural toxins 
through the expression of several ATP-binding cassette (ABC) transporters, the active DNA 
repair capacity, and the relative resistance to apoptosis. 
 
- Unlimited proliferation: stem cells are usually maintained in a quiescent state, but they are 
able to exit and rapidly expand and differentiate in response to stress. This ability depends 
on intrinsic and extrinsic regulatory mechanisms. For example, p53 (a protein usually  
mutated in the tumor), plays a critical role in arresting cell cycle at the G1/S regulation point. 
The microenvironment or “niche” of stem cells is also important. A niche consists of signaling 
molecules, inter-cellular contact, and the interaction between stem cells and the 
neighboring extracellular matrix (ECM). This microenvironment is thought to control genes 
and properties that define “stemness”, the self-renewal ability and development to 
committed cells. This is why stem cells implanted into a totally different niche can potentially 
differentiate into cell types of the new environment. 
 
This last characteristic of the stem cells is much exploited in the clinic, in the treatment of 
various diseases. As a matter of fact, regenerative medicine is an emerging branch of 
medicine with the goal of restoring organ and tissue function for patients with serious 
injuries or chronic diseases (Figure 5). Stem cells have the power to join these damaged 
areas and regenerate new cells and tissues by triggering a repair and renewal process, thus 
restoring functionality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Application of stem cells in regenerative medicine. Ramachandran R.P. and Yelledahalli L.U. Exploring 
the recent advances in stem cell research. J Stem Cell Res Ther 2011; 1:3. 
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Bone marrow transplant is the most widely used stem cell therapy, suitable in the treatment 
of neurodegenerative disease and conditions such as diabetes, heart disease and other 
conditions. For example, embryonic stem cells and umbilical cord blood also shows promise 
in the field of cardiac regeneration, but there is a lot of ethical problems in this application. 
In fact the uses of adult stem cells are morally ethical, but it is unethical to use embryonic 
stem cells since it involves the destruction of the embryos. Excellent progress has been 
made with the discovery that organ regeneration is also possible through stem cells from 
one organ used to form cells of another organ. As a matter of fact, Mesenchimal Stem Cells 
(MSCs) have the capacity to differentiate into several cell types, and they can be isolated 
from adult tissues such as bone marrow and adipose tissue; for example, studies have 
demonstrated their ability to form neural cells both in vitro and in vivo [12]. 
Stem cells are also used as a cancer treatment. Stem cell transplants, from bone marrow or 
other sources, can be an effective treatment for people with certain forms of cancer, such as 
leukemia and lymphoma. While high doses of chemotherapy and radiation can effectively kill 
cancer cells, they have an unwanted side effects, as they can also destroy the bone marrow, 
where blood cells are made. The purpose of a stem cell transplant or a bone marrow 
transplant is to replenish the body with healthy cells and bone marrow when chemotherapy 
and radiation are completed. In some cases, the transplant can  also have an additional 
benefit; the new blood cell may attack and destroy any cancer cells that survived the initial 
treatment [12].  
Despite the above potential benefits of stem cells, these latter could also be regarded as a 
double-edge sword. In fact, it is now known their involvement in the onset of tumors, 
especially at later modifications, derived from the accumulation of gene mutations, in the 
pathways that control their self-renewal ability, such as Wnt, Hedgehog and Notch 
pathways. 
 
 
1.3 Cancer Stem Cells (CSC) 
 
CSC are the evil side of the stem cells, defined as “immortal tumor initiating cells that can 
self-renew and have pluripotent capacity” [13]. Hans Clevers adds that “the CSC concept 
postulates that, similar to the growth of normal proliferative tissues such as bone marrow, 
skin or intestinal epithelium, the growth of tumors is fueled by limited numbers of dedicated 
stem cells” [14]. 
Cancer cells with features of stem cells were discovered by Rudolf Virchow; in the mid – 19th 
century, he found that some cancer cells had histological characteristics and proliferation 
and differentiation capacities similar to embryonic cells. In the seventies, numerous studies 
showed that the tumorigenic ability of cancer cells was different in leukemia and in solid 
tumors. This idea underlined a new concept, that hematologic cancer is a new “stem-cell 
disease”, which is initiated from transformed stem cells and developes as a heterogeneous 
tissue, containing cancer stem cells and differentiated malignant subpopulations [15]. The 
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development of new technologies, such as flow cytometry, has permitted the 
characterization of these cells. The first evidence for CSC was published in 1997 by Bonnet 
and Dick [16], who isolated a rare cellular fraction of leukemia-initiating cells with stem cell-
like features. In their reports, only the CD34+CD38- cell population from acute myeloid 
leukemia (AML) patients could originate hematopoietic malignancy in NOD-SCID mice; 
indeed tumorigenicity in vivo is regarded as the most important CSC feature in the following 
studies of characterization. As a matter of fact, CSC have been consequently characterized in  
most solid tumors like breast, brain, colon, melanoma, pancreatic, prostate, ovarian, hepatic, 
lung and gastric tumors [17,18,19,20]. The first important evidence was the isolation of 
CD44+CD24- breast cancer stem cells from breast cancer patients in 2003 by Al-Hajj et al. 
[17].  
  
On the whole, these investigations have introduced the concept of a hierarchical model to 
explain the heterogeneity of the cancer. Some decades ago the most popular idea was 
represented by the so-called stochastic model, which assumed that every cell within a tumor 
has the same potential to maintain the growth of the tumor; in other words,  there was a 
probability that a specific event in a tumor cell population could transform any tumor cell 
into a tumor-initiating cell [21, 22]. On the contrary, another model, the so-called 
hierarchical model, is now widely accepted; this model assumes that a pool of cancer stem 
cells represents a biologically distinct subset within the malignant cell population, which is 
responsible for  the initiation and maintenance of the a heterogeneous tumor mass 
(Figure6). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 6: Two models to explain the cellular heterogeneity in cancer: the stochastic model and the hierarchy 
model. In the stochastic model, every tumor cell can stochastically generate a tumor. In the hierarchy model, 
only the cancer stem cells (CSCs) will generate tumors. Stem cells – Encyclopedia of Cancer 2012, pp 3517-3523. 
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There is not a firm evidence on the exact origin of the CSC , and different hypothesis have 
been proposed. It is possible that CSC arise by mutation of normal stem cells, and they 
maintain all the stemness features, like self-renewal, asymmetric division, property of 
unlimited proliferation and properties to differentiate into any cell type. However, some 
evidence also indicates that cancer stem cells could arise from mutated progenitor and 
differentiated cells (Figure 7) [23]. Such progenitor and differentiated cells can possess 
proliferation ability with different grade, but they do not have the self-renewal capacity, so 
to become a cancer stem cells they need to acquire specific mutations in genes controlling 
proliferation pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: The origin of the cancer stem cells. Cancer stem cells can arise from mutated normal stem cells, 
progenitor cells and differentiated cells, in response to a selective pressure given by environmental factors. 
Bjerkvig R., Tysnes B.B., Aboody K.S., Najbauer J. and Terzis A. J. A. The origin of the cancer stem cell: current 
controversies and new insights.  Nature Reviews 2005; 5: 899-904. 
 
CSC are distinct populations of tumor cells, and a lot of work has demonstrated some of 
their peculiar properties: 
 
- they are the responsible for the initiation and maintenance of the tumor growth, thanks to 
their self-renewal ability and to their state of quiescence, which permits them to survive in 
specific stress condition like nutrient or oxygen starvation; 
 
- they are chemoresistant, thanks to some specific mechanisms including ABC transporter 
expression, aldehyde dehydrogenase (ALDH) activity, enhanced DNA damage response and 
activation of key signaling pathways [24]; 
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- they are the responsible for cancer recurrence following chemo- or radiotherapeutic 
treatment, since they are able to maintain a state of dormancy [25]. Many of the biological 
mechanisms involved in controlling the dormant state of a tumor can also govern CSC behavior, 
including cell cycle modifications, alteration of angiogenic processes, and modulation of anti-tumor 
immune responses [14]; 
 
- they are responsible for metastasis, since many studies have demonstrated [26] the linkage 
between CSC and epithelial-to-mesenchymal transition (EMT), a key phenomenon in early 
steps of metastasis. Indeed, CSC express some pleiotropic transcriptional factors able to 
induce EMT through disruption of epithelial adhesion and junction, such as Snail, Slug, Zeb1 
and Bmi-1 [27,28]; 
 
- they are characterized by the expression of specific surface markers, which in some cases 
allow their isolation a difficult task due to the fact that they are a rare population (<1% of 
the bulk tumor population). Unfortunately, a universal marker for characterizing the CSC in 
all types of tumors (Table 2) is not available yet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Cancer stem cells markers in different tumors. Miltenyi Biotec antibody for CSC markers. 
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1.3.1 Cancer Stem Cells in ovarian cancer 
 
Recent evidence suggests that ovarian tumors, like other solid tumors, contain distinct 
populations of cells that are responsible for tumor initiation, maintenance and growth. 
Moreover, there is some evidence about the contribution of stem cell dysfunction in adult 
mammalian ovaries to ovarian cancer and polycystic ovary syndrome [29].  
In this context, Bapat and colleagues have reported the first study on the isolation and 
identification of stem-like cells in ovarian cancer [30]. Zhang and colleagues have defined 
two specific markers that recognize a specific cell population with stemness properties, such 
as CD44 and CD117 [31]. CD44 is the receptor for hyaluronic acid and CD117, also known as 
c-Kit, is a tyrosine kinase oncoprotein receptor of the Stem Cell Factor (SCF) cytokine. In 
particular, Zhang and colleagues have analyzed tumor spheroid generation from the ascites 
of 5 patients with serous ovarian cancer; after serial passages in a stem cell-based medium, 
they observed that the surviving spheroid cells were highly enriched in CD44 and CD117 co-
expressing cells (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Spheroids of ovarian cancer stem cells. (Left panel) Sphere forming in specific cell culture conditions, 
without serum and with the addition of specific growth factors; (Right panel) double staining for CD44 and 
CD117 in spheroids by immunofluorescence. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., Yan 
P.S., Huang T. and Nephew K.P. Identification and characterization of ovarian cancer initiating cells from 
primary human tumors. Cancer Research 2008; 68(11): 4311-4320. 
 
 Moreover, these ovarian tumor spheroids cells were characterized by: overexpression of 
stem cell genes, like Bmi-1, SCF, Oct-4, Notch-1, Nanog, Nestin, ABCG2; resistance to 
conventional chemotherapies, such as cisplatin and paclitaxel. One of the most important 
feature, demonstrated in Zhang’s work, was the high tumorigenicity of CD44+ CD117+ cells; 
in particular injection of 100 CD44+ CD117+ cells was tumorigenic in nude mice with tumor 
latencies of 73 to 102 days, whereas the injections of up to 106 bulk tumor cells failed to 
form tumors, tumorigenic with extended latencies [31]. 
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Other reports demonstrate different ovarian CSC markers [32]. For example, one of the most 
widely described is CD133 or Prominin, that is a membrane glycoprotein encoded by the 
CD113/Prom-1 gene. CD133 was first detected as a marker of hematopoietic stem cells and 
then Baba and colleagues [33] have isolated CD133+ cells in ovarian cancer cell lines and in 
primary ovarian tumors. In particular, they have demonstrated that CD133+ cells have a 
significantly enhanced capacity to form tumors following injection in to 
immunocompromised mice, compared to the CD133- cell fraction. Moreover, tumors derived 
from CD133+ cells comprise both CD133+ and CD133- cells, suggesting that CD133+ cells could 
regenerate two phenotypically distinct populations. Unfortunately, the specificity of this 
marker is uncertain, because other studies have shown that isolated CD133- cells are also 
able to generate tumors. There are two possible explanations about these results: the first is 
that the tumor-initiating capacity derived is due to a small percentage of CD133+ cells 
contaminating the largely purified CD133- population; the second is that another ovarian 
cancer stem cell population that is not characterized by CD133 expression could give rise to 
CD133 cells with tumor-initiating capacities [34] (Figure 9). 
 
 Another marker of ovarian cancer stem cells is ALDH (aldehyde dehydrogenase isoform 1), a 
detoxifying enzyme involved in the phenomenon of chemo resistance. As a matter of fact, 
cells with active ALDH (ALDH+) isolated from ovarian cancer cell lines are chemo resistant 
and more tumorigenic than ALDH- cells [35]. This chemo resistance was also demonstrated 
by Landen and colleagues, who through experiments of ALDH gene silencing demonstrated 
that the down-regulation of ALDH1A sensitized resistant cells to chemotherapy both in 
culture and in an in vivo xenograft model [36]. 
In reference to the idea that the isolation of CSC is more effective through the overlapping 
expression of two or more CSC markers, Silva and colleagues reported the existence of a 
highly proliferative ALDH+CD133+ cell fraction in ovarian cancer cell lines. Moreover, ovarian 
tumor-derived ALDH+CD133+ cells had high tumor initiating capacity and formed tumors with 
shorter latency compared to the ALDH-CD133+, ALDH+CD133- and ALDH-CD133- cell 
populations (Table 3) [35]. 
 
Finally, ovarian CSC have also been identified as the so-called “Side Populations” (SP), in view 
of the property of CSC to efflux toxins like chemotherapeutic agents via members of the 
ATP-binding cassette transporter families, such as ABCG2. This property has allowed the 
identification of a side population fraction with enhanced ability to efflux lipophilic 
substrates like the dye Hoechst 33342. Many studies have demonstrated in SP cells the 
following characteristics:  tumorigenicity, resistance to cytotoxic treatment and expression 
of stemness and multi-drug resistance genes [37]. 
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Figure 9: Sorted CD133
+
 and CD133
- 
cells generate histologically similar tumors that contain CD133
+
 cell 
fraction. Curley M.D., Therrien V.A., Cummings C.L., Sergent P.A., Koulouris C.R., Friel A.M., Roberts D.J., Seiden 
M.V., Scadden D.T., Rueda B.R., Foster R. CD133 expression defines a tumor initiating cell population in primary 
human ovarian cancer. Stem Cells 2009; 27:2875-2883. 
 
 
 
Cell type ALDH−CD133+ ALDH+CD133+ ALDH+CD133− ALDH−CD133− 
No. of cells 
injected 
Tumors formed Tumors formed Tumors formed Tumors formed 
10–500 0/9 4/9 0/9 ND 
5,000 ND ND 0/5 0/9 
50,000 ND ND ND 0/9 
  
Table 3: Tumor initiating capacity of limiting diluitions of ALDH
+/-
CD133
+/-
 cells from primary human ovarian 
tumors. Silva I.A., Bai S., McLean K., Griffith K., Thomas D., Ginestier C., Johnston C., Kueck A., Reynolds R.K., 
Wicha M.S., Buckanovich R.J. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian 
cancer stem cells that portend poor patient survival. Cancer Res 2011; 71:3991-4001. 
 
Unfortunately, these studies show some discrepancies, such as in one work the SP fraction 
has been isolated in paclitaxel-resistant cell lines, but not in the cisplatinum-resistant 
fraction, and it is unclear whether SP is correlated with multidrug resistance [38]. Moreover, 
SP cells are more prominent in ascites, recurrent tumors and disseminated in the peritoneal 
cavity; however a correlation between SP and disease stage was not significantly 
demonstrated [39]. 
 
These premises suggest that CD117 is the marker that best allows the isolation of a cell 
population characterized by self-renewal, tumor-initiating capacity and chemo-resistance. 
Moreover, CD117+ cells with stemness phenotype have been isolated not only in cell lines 
but also in primary samples with different grade of tumor dissemination and metastasis. 
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CD117 (c-Kit) is a well-known tyrosine kinase and for this reason it is an attractive target for 
cancer therapy.  
 
Ovarian CSC have been analyzed in the last years for many characteristics, which allow their 
survival and proliferation and consequently the maintenance of tumor growth. Several 
developmental pathways, including Notch, Wnt, Hedgehog and transforming growth factor-
β (TGF-β) are crucial for the regulation of self-renewal. In particular, TGF-β plays a key role in 
the modulation of EMT (epithelial mesenchimal transition) and in the induction of CSC 
migratory properties [40]. 
Moreover, there are some genes involved in the regulation of ovarian tumor-initiating cells. 
For example p53, a tumor suppressor protein, is related to the pathogenesis of high-grade 
serous adenocarcinoma of the ovary; recent work has demonstrated that ovarian CSC can be 
generated by silencing of p53 expression in tumor cells [41], in support of the idea that p53 
dysfunction can enhance the self-renewal ability of ovarian stem-like tumor cells. Recently, 
Chau and colleagues have shown the importance of c-kit  in the regulation of survival of 
ovarian CSC as well as their chemo resistance, through some demonstrated pathways 
mediated by phosphoinositide 3-kinase (PI3K)/Akt and Wnt/β –catenin- ATP-binding cassette 
G2 (ABCG2). C-Kit is overexpressed in ovarian CSC and solid evidence has shown that 
knockdown of c-kit expression or inhibition of its activity by Imatinib decrease the 
tumorigenic capabilities  and chemo resistance [42].          
Lastly, also miRNA have recently emerged as an important regulator of CSC. The most 
important, characterized in ovarian CSC, are miR-214, miR-199a and miR-200. In particular 
miR-199a suppresses the tumorigenicity and chemo resistance of the CD44+CD117+ cell 
fraction, through the repression of CD44 expression, that in turn inhibits migration and 
invasion of these cells. 
 
All the above features could be a potential target to improve ovarian cancer therapy, but a 
new idea is that capacity of self-renewal could also be maintained by the surrounding 
environment. In particular, the CSC niche in ovarian cancer includes immune cells, stromal 
cells, blood vessels and extracellular matrix components. All these cell types could be a 
target for therapy; indeed several biological processes, that occure in CSC niche, including 
inflammation, hypoxia and angiogenesis could be important to determine the fate of CSC. 
For these reason it is really fundamental to focus on tumor microenvironment to find the 
fundamental mechanisms of CSC survival and maintenance (Figure 10) [43].  
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Figure 10: The tumor microenvironmet involved in the maintenance and regulation of ovarian cancer stem 
cells. Kwon M.J. and Shin Y.K. Regulation of ovarian cancer stem cells or tumor-initiating cells. Int. J. Mol. Sci. 
2013; 14:6624-6648. 
 
 
 
1.4 Role of cancer stem cells in chemoresistance and 
importance of targeting CSCs 
 
One of the most important features of the CSC is their chemo resistance, in view of its 
fundamental implication in the clinics. As a matter of fact, all the current therapeutic 
strategies against cancer have severe limitations that frequently lead to treatment failure. 
The reason is that these strategies is not selective against CSC; thus, the incidence of 
recurrence and metastasis is high, because these therapies cannot eliminate CSCs. Several 
pathways could be involved in these mechanisms, including activation of anti-apoptotic 
factors, inactivation of pro-apoptotic effectors, and  reinforcement of survival signals. These 
survival signals are: efficient DNA repair mechanisms, expression of drug pumps and altered 
cell-cycle. Moreover, CSC are mostly quiescent and therefore can escape chemotherapy-
induced cytotoxicity which acts on dividing cells. 
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Based on these premises, it is essential to develop treatments that target CSC, but the 
challenges are formidable (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure11: “Stemline therapy”, the new therapy must to target Cancer Stem Cells. Reya T., Morrison S.j., Clarke 
M.F. and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-111. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Therapies targeting cancer stem cells. Targeting surface markers of CSCs (red area), specific 
pathways involved in the self-renewal (green area), inhibiting ABC cassette (purple area), targeting 
microenvironment (blue area). Chen K., Huang Y. and Chen J. Understanding and targeting cancer stem cells: 
therapeutic implications and challenges. Acta Pharmacologica Sinica 2013; 34: 732-740. 
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Targeting CSC might be a strategy to improve outcome of cancer patients but the 
complexities that lie within this approach will provide many problems in clinical applications. 
Some of these hurdles include overcoming the immune heterogeneity in CSC population as 
well as the problem of epitopes shared with normal stem cells  and the necessity to identify 
additional CSC antigens. Indeed, drug treatment for CSC may increase the risk of toxicity 
since CSC share common features with normal stem cells. 
 
The current therapeutic strategies targeting CSC [44, 45] are discussed below (Figure 12). 
Important interest has been generated in the development of monoclonal antibodies to 
target CSC markers of CSCs. For example Imatinib, a potent CD117 (c-KIT) specific inhibitor, 
has been used in clinical trials for the treatment of many types of cancer, including epithelial 
ovarian cancer [45].  
Researchers have also designed numerous pharmacological agents that can interact with 
ABC transporters, to inhibit multidrug resistance. In this regard, Verapamil was the first 
identified inhibitor, often used in side population analysis to block the exclusion of the dye 
Hoechst. Moreover, the combination of Tariquidar, another inhibitor, and Docetaxel is under 
investigation in ovarian cancer [46].  
Another therapeutic strategy could be the induction of differentiation and loss of the self-
renewal properties. Drugs such as retinoic acid or drugs that aim to generate epigenetic 
changes in the tumor can stimulate CSC differentiation.  Whitworth and his colleagues 
reduced growth of ovarian CSC with carboplatin combined with three novel retinoid 
compounds [47]. Moreover, it is possible to find some specific inhibitors of the pathways 
that control self-renewal and cell fate decisions of stem cells and progenitor cells, such as 
Wnt, Hedgehog and Notch. Recently, McAuliffe and colleagues have demonstrated the 
importance of the Notch signaling pathway and Notch3 in particular in the regulation of CSC 
in ovarian cancer; interestingly they have shown that γ-secretase inhibitor (GSI), a Notch 
pathway inhibitor, depletes efficiently CSC [48]. 
Last but not least, tumor microenvironment has assumed a prominent importance in the last 
years, in term that it can create a niche to protect CSCs from drugs and specific nutrient or 
oxygen stress. The supporting role of the microenvironment in tumor growth and 
progression, including metastasis formation, clearly puts the CSC niche and, especially, the 
mediators of this interaction in the spotlight as future therapeutic targets [49]. 
Taking up the words of Weinberg in his seminal work “tumors have increasingly been 
recognized as organs  and the biology of a tumor can only be understood by studying the 
individual specialized cell types within it as well as the tumor microenvironment that they 
construct during the course of multistep tumorigenesis” [50]. Tumor microenvironment 
include many cell types such as endothelial cells, immune inflammatory cells, cancer 
associated fibroblasts; all these cells could be a suitable therapeutic target. But tumor niche 
also means the conditions in term of oxygen, nutrients, metabolites in which the cells grow, 
~ 26 ~ 
 
thus constraining or permitting cell survival. For this reason in the last decades targeting 
cellular metabolism acquired a high interest, to improve cancer therapeutics. 
 
 
1.5 Metabolism of cancer – Warburg effect 
 
Cancer cells, unlike normal cells, privilege conversion of pyruvate to lactic acid for ATP 
generation rather than mitochondrial oxidative phosphorylation even in the presence of 
oxygen: this peculiar metabolic profile is termed aerobic glycolysis or the “Warburg effect” 
(Figure 13). 
 
 
Figure 13: Warburg effect – aerobic glycolysis. Heiden MGV et al. Understanding the Warburg Effect: The 
Metabolic Requirements of Cell Proliferation. Science 2009; 324:1029.  
 
Otto Warburg is a Nobel prize-awarded scientist (for the discovery of yellow enzymes 
(Flavins) and cytochrome oxidase). In 1930, Warburg observed an altered metabolism in 
cancer cells. In particular, by using a manometer, Warburg and his colleagues found that 
cancer cells did not consume more oxygen than normal tissue cells, even under normal 
oxygen circumstances [51]. Initially Warburg assumed that cancer cells had an impaired 
respiration due to the functional defects in mitochondria [52]. However, subsequent work 
showed that  mitochondrial function is not impaired in most cancer cells, suggesting an 
alternative explanation for aerobic glycolysis in cancer cells. To explain the phenomenon 
observed, Warburg speculated some differences between normal cells and cancer cells. 
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Normal cells are characterized by a specific bioenergetics, essential to convert energy 
substrates (carbohydrates, proteins and lipids) in several metabolic intermediates that are 
used to synthesize nucleic acids, amino acids, glycogen  and other biomolecules required for 
normal body functioning. In particular glucose, derived by the processing of carbohydrates, 
enters the cells through specific glucose transporters. In the cytosol, several enzymes 
catalyze glycolysis that ends with the production of pyruvate, which enters the mitochondria 
and it is converted to acetyl CoA by pyruvate dehydrogenase (PDH). Acetyl CoA condenses 
with oxaloacetate (OAA) to form citrate, which is completely oxidized in the Trichloeoacetic 
(TCA) cycle to generate reducing equivalents for the respiratory chain. The result of this 
metabolism called oxidative phosphorylation, in term of energy produced, is 2 ATP 
molecules from glycolysis and 34 ATP molecules from the respiratory chain. Therefore, 
normal cells in  the presence of oxygen are able to produce 36 ATP molecules, which 
represent about the 90% of the energy requirements for the survival of a cell.  
In some cases, the cells must survive in oxygen stress conditions, and they are able to switch 
their metabolism to anaerobic glycolysis. In particular, the cells can redirect the pyruvate 
generated by glycolysis away from mitochondrial oxidative phosphorylation by generating 
lactate, that allows glycolysis to continue by cycling NADH back to NAD+, but results in 
minimal ATP production. 
 
Cancer cells, according to the theory of Warburg, are characterized by an aerobic glycolysis, 
that means the ability to convert most glucose to lactate regardless of whether oxygen is 
present. It is conceivable that fast-growing cancer cells require more energy than normal 
cells and it is ironic to realize that, unlike normal cells, tumor cells use an inefficient reaction 
to generate considerable amounts of their energy. There are some specific reasons of this 
bioenergetics alteration and it is necessary to keep in mind that cancer cells must implement 
metabolic processes in very different and stressful environments, where nutrients supply 
may be low and where redox balance, pH and oxygen levels may not be maintained. First  of 
all, the metabolism of cancer cells have to be adapted to facilitate the uptake and 
incorporation of nutrients into the biomass needed to produce a new cell: amino acids for 
protein synthesis, nucleic acids for DNA duplication and lipids for cell membrane synthesis. 
Moreover, glycolysis provides acidic environment, which is harmful to normal cells but has 
no effect onj tumor cells, underscoring the importance of glycolysis as a cellular defense 
mechanism for cancer cell growth. A third hypothesis is that glycolysis produces less reactive 
oxygen species (ROS), so that the genome of cancer cells might elude the damage incurred 
by high concentration of ROS. At the end, it is clear that glycolysis produce less ATP than 
oxidative phosphorylation, but it is reasonable to think that cancer cells need more 
metabolic intermediates than the simple ATP, which are essential to maintain their survival 
also in stress conditions. 
Even though metabolism reprogramming in cancer cells is universally accepted as one of the 
hallmarks of cancer [3] and many questions about the efficiency of the Warburg effect 
remain largely unanswered, the Warburg’s finding are exploited clinically by 18F-
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deoxyglucose positron emission tomography scanning, known as PET, for solid tumor 
detection. The 18F-FDG is a glucose analogue which enters the cell in normal ways and it is 
phosphorylated like normal glucose to prevent its processing by glycolytic pathways before 
radioactive decay; thus, this parameters is a good reflection of glucose uptake in the body 
[53]. This ability to monitor glucose within tumors and the increase in glucose uptake by 
tumor cells confirm the Warburg’s hypothesis and underline the importance of glucose in 
cancer metabolism and the contribution of this finding to clinical diagnosis.  
 
Our major open question about cancer cell metabolic profile (Figure 14) is whether gene 
alterations could precede and cause metabolic derangements, or rather a special metabolic 
profile due to the energetic need of cancer cells could translate into genetic abnormalities. 
 
 
Figure 14: Cancer metabolism. Paolo E. Porporato, Suveera Dhup, Rajesh K. Dadhich, Tamara Copetti and 
Pierre Sonveaux. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. 
Pharmacol. 2011. 
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In fact, mutation of oncogenes or tumor suppressor genes is a well-known direct cause of 
cancer; on other hand, metabolic stresses, typical of tumor environment, may cause tumor-
associated gene alterations and increment the probability of tumor growth. In this regard, 
mutations in metabolic genes also causes certain types of tumors and many of these genes 
encoding for mitochondrial enzymes, underlining the Warburg’s hypothesis that cancer cells 
have primary defects in mitochondria.  
The importance of some specific mutations in genes encoded metabolic enzymes is known: 
succinate dehydrogenase (SDH) [54], which catalyzes the conversion from succinate to 
fumarate in the TCA reactions, isocitrate dehydrogenase 1 (IDH1) [55], which converts 
isocitrate to α-ketoglutarate (α-KG), and pyruvate kinase form 2 (PKM2) [56], which is the 
key enzyme in the conversion of phosphoenol-pyruvate into pyruvate at the last second step 
in glycolysis. 
At the end, one of the most important metabolic regulator is hypoxia-inducible factor (HIF), 
that is involved as a regulatory factor during hypoxia, a common phenomenon in tumors [57, 
58]. HIF controls the expression of many target genes, such as genes encoding glucose 
transporters (GLUT), glycolysis enzymes like pyruvate dehydrogenase kinase (PDK) and 
lactate dehydrogenase A (LDH-A). Amplification of GLUT may allow cancer cells to compete 
with normal cells in the process of glucose uptake, while the up-regulation of PDK is able to 
inhibit the activity of pyruvate dehydrogenase (PDH), and the increased levels of LDH-A can 
accelerate the conversion of pyruvate to lactate. For these reasons, HIF target genes 
promote the Warburg effect. 
 
All these premises show that there is still much to learn about how proliferating cell 
metabolism is regulated and many questions needed to be answered, such as if the 
metabolic properties of cancer cells are remarkably different from those of normal cells and 
if targeting metabolic enzymes could improve the efficacy of cancer therapy and overcome 
therapeutic resistance. In reference to Cancer Stem Cells, it is an exciting challenge to 
investigate of the CSC metabolism. In particular, little if anything is known about the 
metabolic profile of CSC and it is unclear whether CSC also present a prominent Warburg 
effect.  
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1.6 Therapies targeting the metabolic profile in cancer – 
possible targeting of CSC 
 
The therapeutic window for targeting CSC includes two fundamental properties, possibly 
involved in the failure of current therapies: the chemo resistance and the dysregulation of 
metabolism. These two features are probably connected, but the molecular mechanisms by 
which targeting metabolism could impair chemo resistance is not fully understood and 
deserves further investigations. Given the explosion of interest and information on cancer 
metabolism, it is hoped that new therapies will emerge in the next decades; nonetheless 
there are already some drugs approved for clinical use in certain types of cancer and others 
under preclinical examination. 
 
The dependence of cancer cells on aerobic glycolysis (Warburg effect) for ATP generation 
has been exploited as a target for anticancer therapies and many possibilities have been 
proposed [59] (Table 4). 
 
a) The reduction of glucose entry into the cell, even though the toxicity associated to 
the glucose deprivation may be a major challenge for the use of this approach. 
Nonetheless, there are some drugs that reduce glucose uptake. For example: 
Imatinib (Glivec) is a tyrosine kinase inhibitor that leads to the internalization of cell 
surface GLUT1 (glucose transporter) and reduce glucose uptake [60]; 2-deoxyglucose 
(2-DG), a glucose analog, competes with glucose for transport across the cell 
membrane and, inside the cells, it is phosphorylated by the early enzymes of the 
glycolysis into 2-DG-6-phosphate, thus inhibiting glycolysis [61].  
b) The inhibition of some fundamental enzymes of glycolysis, such as PKM2. TT-232 is 
an inhibitor of this enzyme [62]. 
c) The inhibition of pentose phosphate pathways (PPP), deemed as an important 
pathway for its role in the synthesis of nucleic acids, that are indispensable for rapid 
cell proliferation, and for production of NADPH, that reduces the oxidative stress. An 
analog of NADP (6-aminonicotinamide, 6-AN), inhibits glucose-6 phosphate 
dehydrogenase (G6PD, the first enzyme of the PPP pathway), thus increasing 
oxidative stress and reducing tumor growth [63]. However, different results have 
been obtained by Herter and colleagues, who demonstrated the neurotoxicity of high 
doses of 6-AN  and the lack of anticancer activity of well-tolerated dose [64].  
d) The inhibition of HIF-1, one of the most important regulators of glucose metabolism 
in cancer cells. Topotecan is an inhibitor of HIF-1 and promotes oxidative 
phosphorylation in tumor cells [65].  
e) The promotion of oxidative phosphorylation in cancer cells, dependent on glycolytic 
metabolism. Different mechanisms have been proposed for the activation of 
mithocondrial respiration, such as the down-regulation of lactate dehydrogenase 
(LDH) by small interfering ribonucleic acid (siRNA) to prevent the conversion of 
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pyruvate in lactate [66] or the inhibition of pyruvate dehydrogenase kinase 1 (PDK1), 
which inhibits PDH the key enzymes of the TCA cycle, by antisense oligonucleotides 
[67]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Anticancer therapies targeting aerobic glycolysis. Abbreviations: 2-DG, 2-deoxyglucose; LND, 
lonidamine; 3-BrPA, 3-bromopyruvate; 3-PO, 3-(3-pyridinyl)-l-(4-pyridinyl)-2-propen-l-one; 6-AN, 6-
aminonicotinamide; DCA, dichloroacetate; GA, geldanamycin; 2ME2, 2-methoxyoestradiol; PX-478, S-
2-amino-3-[4′-N,N,-bis(2-chloroethyl)amino]phenyl propionic acid N-oxide dihydrochloride. Upadhyay 
M
1
, Samal J, Kandpal M, Singh OV, Vivekanandan P.  The Warburg effect: insights from the past 
decade. Pharmacol Ther. 2013 Mar;137(3):318-30.  
 
 
 
Mechanism of action 
Target 
gene 
Inhibitor(s) Reference(s) 
Reduction of glucose entry into 
the cell 
GLUT1 
Imatinib Barnes et al., 2005 
2-DG Maher et al., 2005 
Phloretin Cao et al., 2007 
Fasentin Wood et al., 2008 
Inhibition of phosphorylation of 
glucose 
HK 
LND Floridi et al., 1981 
3-BrPA 
Chen et al., 2007 and Zhang et 
al., 2012 
Mannoheptulose 
Board et al., 1995, Scatena et al., 
2008 and Pathania et al., 2009 
Methyl jasmonate Madhok et al., 2011 
Inhibition of fructose-6-PO4 to 
fructose-1,6-bisphosphate 
PFK1 3-PO Clem et al., 2008 
Inhibition of 
phosphoenolpyruvate to 
pyruvate 
PKM2 
TT-232 
Flourophosphates creatine 
phosphate oxalate, l-
phospholactate 
Szokoloczi et al., 2005 
Madhok et al., 2011 
Suppression of pentose 
phosphate pathway 
TKTL1 Oxythiamine Rais et al., 1999 
G6PD 6-AN 
Kohler et al., 1970 and Varshney 
et al., 2005. 
Promotion of pyruvate entry 
into mitochondria 
PDK1 DCA Michelakis et al., 2008 
Reduction of HIF-1 activity HIF-1α 
Topotecan 
Rapisarda et al., 
2002 and Rapisarda et al., 2004 
Digoxin Zhang et al., 2008 
YC-1 Semenza, 2003 
GA Isaacs et al., 2002 
2ME2 Mabjeesh et al., 2003 
PX-478 Welsh et al., 2004 
Echinomycin Cairns et al., 2007 
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Moreover, recent studies suggest that targeting mitochondria is an attractive strategy for 
cancer therapy and the term “mitocans” has been used to classify mitochondria-targeted 
anticancer drugs [68]. The reason of this interest is that the Warburg’s hypothesis of the 
defects in mitochondria is not totally unfounded and cancer cells exhibit various degrees of 
mitochondrial dysfunction, such as changes in energy metabolism, increased 
transmembrane potential and ROS production. In particular, the increase in ROS production 
by cancer cells is associated with multiple changes in cellular functions, such as cell 
proliferation, migration, differentiation and apoptosis, all fundamental properties of cancer 
cells.  
Finally, we need to mention the most innovative drugs used to target mitochondrial 
functions: Metformin and CPI-613. 
Metformin (Figure 15), one of most widely prescribed oral hypoglycemic agents, has recently 
received increased attention because of its potential antitumorigenic effects that are 
thought to be independent of its hypoglycemic activity. This has been evaluated in multiple 
in vitro and in vivo studies, and it is now being tested in clinical trials as an adjuvant to classic 
chemotherapeutic regimens [69, 70]. Specifically, this compound exerts its pharmacological 
effects by inhibiting the mitochondrial ETC and by activating the AMPK pathway. Because, 
Metformin induces metabolic stress by reducing mitochondrial ATP production, it has been 
suggested that it could inhibit the growth of cancer cells by decreasing the cellular energy 
status. 
 
Figure 15: Metformin and cancer therapy. Luengo et al. BMC Biology 2014 12:82    
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CPI-613 is an analog of lipoic acid capable of disrupting mitochondrial metabolism and it 
seems to exhibit selective effects against cancer cells both in vitro and in vivo [71]. CPI-613 is 
an innovative drug, actually in clinical trial, targeting two key enzymes of the TCA cycle: 
pyruvate dehydrogenase kinase (PDK) and alpha-ketoglutarate dehydrogenase (α-KGDH) 
(Figure 16). In specificity, it stimulates PDK and consequently it induces the inactivation of 
PDH through phosphorylation, activating multiple tumor cell death pathways. Moreover, it 
induces of α-KGDH with an endogenous redox mechanism. So this single drug 
simultaneously and independently attacks two central, essential mitochondrial metabolic 
complexes. 
 
 
 
 
Figure 16: CPI-613 and target therapy in mitochondria. Paul M. Bingham and Zuzana Zachar The Pyruvate 
Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy. 
 
The possibility that Metformin could efficiently target CSC [69, 70], suggests that this rare 
cell population is characterized by a different metabolism that the cancer cells, privileging a 
mitochondrial-dependent metabolism. 
In view of the novelty of the drug, there is no significant evidence about the capacity of CPI-
613 to induce the death of CSC. It has to keep into account that CSC could have different 
metabolic profiles depending on their tissue of origin and their degree of differentiation. For 
example, highly undifferentiated liver cancers tend to be more glycolytic than differentiated 
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cells [73], while a recent study using glioma stem cells show that these cells consume less 
glucose and produce less lactate, compared to their cancer cell counterpart [74].    
 
In conclusion, the idea that CSC are characterized by a different metabolism than the cancer 
cells, could open new avenues to new target therapies.  
The niche is the source of molecules that activate or inhibit signal transduction pathways 
and, while the stem cell microenvironment of a normal tissue is known to maintain a balance 
between self-renewal and differentiation, the tumor  microenvironment predominantly 
displays proliferating signal to cancer cells and CSC. Accordingly, anti-metabolic 
reprograming strategies begin to provide a roadmap for the generation of novel “metabo-
stemotoxic” therapies, counteracting therapeutic resistance, cancer aggressiveness and 
cancer recurrence.                                                                                                                                                                                                                                                           
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1.7 Aims of the project 
 
 
The aims of this project are: 
a) The phenotypic characterization of CSC in ascitic effusions from ovarian cancer-
bearing patients. The characterization will be carried out through the application of 
techniques such as: stemness marker expression, spheroid formation, chemo 
resistance assay and tumorigenicity in vivo.  
 
b) The investigation of the metabolic profile of CSC isolated from patients with 
epithelial ovarian cancer, through specific metabolic assays to evaluate whether the 
CSC fraction is characterized by the known Warburg effect or by other particular 
metabolic pathways. 
These studies have the ambition to define differences between CSC population and the non-
stem counterpart, in order to discover specific therapeutic targets, because it is known that 
the niche protect CSC from drugs and specific nutrient or oxygen stress. 
For this reason, we will also focus our attention on a key nutrient stress, glucose deprivation, 
to test the addiction of CSC to this nutrient and their ability to survive under starvation 
conditions. These experiments could in fact demonstrate in vitro the ability of CSC to persist 
in stress condition. 
The final aim is to find a specific drug or drug combination that targets the relevant 
metabolic pathways.                                                                                        
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2.  MATERIALS AND METHODS 
 
2.1 Primary samples and in vitro culture 
Ascitic fluid and tumor samples of EOC patients were obtained following informed consent 
from 45 patients. Cells were maintained in RPMI-1640 medium supplemented with 10% 
fetal bovine serum (FBS; GIBCO Invitrogen, Monza, Italy), 1% sodium pyruvate (Lonza, 
Basel, Switzerland), and 1% L-glutamine (GIBCO). Cells were cultured at 37°C, 5% CO2, and 
harvested at confluence using trypsin-EDTA (Invitrogen). In a set of experiments, the cells 
were cultured in the absence of glucose; at the end of the starvation period, glucose was 
added and marker expression evaluated 10 days later. In another set of experiments, the 
cells were cultured for 14 days in the absence of glucose, and then transferred to medium 
without glucose, without glucose and L-glutamine, or without glucose, L-glutamine and 
sodium pyruvate.  
2.2 Cell lines  
IGROV-1 cells were purchased from ATCC (Manassas, VA) and OC316 cells were kindly 
provided by S.Ferrini (IST, Genoa, Italy); the cell lines were used within six months from 
resuscitation. The cells were maintained in RPMI-1640 medium (GIBCO) supplemented with 
10% FBS (GIBCO, Invitrogen), 1% sodium pyruvate (Lonza), 1% penicillin-streptomycin 
(Lonza) and 1 % L-glutamine (GIBCO). The cells were cultured at 37°C in a humidified 
atmosphere containing 5% CO2 and harvested, when 80-90% confluent, using Trypsin-EDTA 
(Invitrogen). 
2.3 Flow cytometry  
The cells were stained with Live-Dead (Pacific Blue, 1:600; Invitrogen) to discriminate living 
cells. The following anti-human monoclonal antibodies were used: anti-CD44 (1:1,000; 
Abcam, Cambridge, U.K.), anti-CD117 (non-activating AC126 clone, 1:10; Miltenyi Biotec, 
Bergish Gladbach, Germany), anti-CD45 (1:10; Miltenyi Biotec), anti-CK7 (1:25; Abcam), 
anti-GLUT1 (1:1,000; Abcam). Intracellular staining was performed after fixation with 4% 
paraformaldeyde and permeabilization with 0.1% Triton X-100. After incubation with 
unconjugated antibodies, the cells were incubated for 30 min with the appropriate 
secondary antibody (Alexa 1:500; Invitrogen). All the cytofluorimetric analyses were 
performed using a FACS LSRII (BD Bioscience, Franklin Lakes, NJ); data were collected from 
at least 1 x 105 cells/sample and elaborated with FlowJo software (TreeStar, Ashland, OR). 
For FACS-sorting, antibody-labelled cells were separated with a MoFlo Astrios Cell Sorter 
(Beckman Coulter, Brea, CA); the purity of the sorted populations always exceeded 90%. 
To evaluate glucose uptake, EOC effusion cells were labelled with anti-CD44 and anti-CD117 
antibodies; 2-NBGD-FITC glucose (12.5 µM; Invitrogen) was then added and fluorescence 
intensity measured after 1 min. Cell viability was evaluated by incubating the cells for 15 
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min at 37°C with AnnexinV/PI staining kit (Roche, Basel, Switzerland); unless otherwise 
specified, results were expressed as the ratio between the percentage of Annexin Vneg/PIneg 
cells at the experimental time points and the percentage at time 0.  
To evaluate the effect of glucose starvation on cell proliferation, EOC effusion cells were 
stained with PKH26 (Sigma Aldrich, St. Louis, MO) as described elsewhere [31] and seeded 
at 2x105 cells/well in RPMI medium or RPMI without glucose (Sigma Aldrich), both 
supplemented as above. Flow cytometry analysis was performed 14 days later.  
2.4 Spheroid formation assay and in vitro cell differentiation 
 
To promote in vitro spheroid formation, EOC ascitic effusion cells were seeded in poly-2-
hydroxyethyl methacrylate (PhEMA)-coated plates (BD Bioscience, Franklin Lakes, NJ) in 
serum-free RPMI medium supplemented with bFGF (10 ng/ml) and EGF (20 ng/ml: both from 
Peprotech, Rocky Hill, NJ) at a density of 2 x 104 cells/well. Medium was replaced every 7 
days. 
To determine the frequency of spheroid-forming precursors, we performed an extreme 
limiting dilution analysis (ELDA) in unsorted EOC cells, and FACS-sorted CD44+CD117+ and 
CD44+CD117- cells. Briefly, the cells were plated at different concentrations in 96-well flat-
bottom ultra-low attachment PhEMA-coated plates (BD Bioscience) in a total volume of 0.1 
ml of serum-free medium RPMI medium supplemented with EGF and bFGF. Thirty replicate 
wells were set up for each cell concentration. After 7 days of incubation, the wells were 
scored for spheroid formation; the frequency of spheroid-forming precursors in each 
population was calculated by ELDA web tool (http://bioinf.wehi.edu.au/software/elda). Data 
are expressed as the number of spheroid-forming cells/103 cells. 
The ability to differentiate in vitro was evaluated by plating unfractionated EOC cells, 
previously cultured in serum-free conditions, in the presence of 10% FBS at a density of 2 x 
104 cells/ml. The cells were maintained at 37°C in a 5% CO2 humidified atmosphere, and the 
medium replaced every 7 days. 
2.5 Chemotherapy sensitivity assays 
To assess chemotherapy resistance, unfractionated EOC effusion cells were seeded at 2 x 105 
cells/well in 6-well plates in complete RPMI medium in the presence or in the absence of 
Doxorubicin (1 µM; Ebewe Pharma, Wien, Austria); cytofluorimetric analysis was performed 
48 h later. 
2.6 In vivo xenograft propagation 
Xenografts were generated by injecting intra-peritoneally (i.p.) 1 × 106 tumor cells, obtained 
from primary EOC effusion samples, into severe combined immunodeficient (SCID) mice as 
reported elsewhere [1] Mice were purchased from Charles River (Wilmington, MA); 
procedures involving animals and their care were performed according to institutional 
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guidelines that comply with national and international laws and policies (EEC Council 
Directive 86/609, OJ L358, 12 December 1987). About 2 months later, animals developed 
tumors, which contained a predominant ascitic component. 
2.7 Tumorigenicity assay  
To demonstrate the  tumorigenic potential of the different EOC populations, different 
numbers of ex vivo FACS-sorted CD44+CD117+ and CD44+CD117- cells were injected i.p. into 
seven-to nine-week-old Rag-2 y-/- mice in a total volume of 300 µl. To evaluate the 
tumorigenic potential of glucose-starved cells, 5 x 103 cells, cultured for 14 days as above in 
the presence or in the absence of glucose, were injected i.p. into Rag-2 y-/- mice. At tumor 
establishment, mice were sacrificed, tumors harvested and isolated cells analyzed by FACS.  
2.8 RNA extraction, reverse transcription and gene card analysis  
Total RNA was extracted by the TRIzol method according to manufacturer’s instructions. 
cDNA was synthesized from 0.5-1 μg of total RNA with Superscript II reverse transcriptase 
(Invitrogen), and hybridized to TaqMan Custom Arrays specific for 62 genes (Applied 
Biosystems, Foster City, CA), with each sample run in triplicate. The PCR step was 
performed using an ABI PRISM® 7900HT Sequence Detection System (Applied Biosystems). 
Results were analyzed using the comparative ΔΔCt method; ΔΔCt values were utilized to 
calculate the RQ=2-ΔΔCt. Data were expressed as the fold difference in gene expression 
(normalized to the housekeeping gene β2-microglobulin) relative to a reference sample, as 
indicated in the individual figure legends. qRT-PCR efficiency ranged from 95% to 105%.  
2.9 Western blotting (WB) 
FACS-sorted CD44+CD117+ and CD44+CD117- cells were lysed and subjected to SDS-PAGE and 
WB. Immunoreactivity was evaluated using the following rabbit antibodies: anti-actin 
(1:5,000; Sigma Aldrich), anti-PDHK1 (1:1,000; Cell Signaling, Boston, MD), anti-phospho-PDH 
(1:1,000; Abcam), anti-PDH (1:2,000; Abcam) and anti-G6PD (1:1,000; Cell Signaling). Mouse 
anti-IDH2 (1:10,000) and anti-MCT4 (1:1,000) were purchased from Cell Signaling; goat anti-
HKII (1:1,000) from Santa Cruz (Dallas, TX). The blots were hybridized with a 1:5,000 dilution 
of HRP-conjugated anti-goat, anti-mouse or anti-rabbit antibody (Amersham-Pharmacia, 
Little Chalfont, U.K.), as appropriate. Finally, the signal was detected by chemiluminescence 
with SuperSignal kit (Pierce, Rockford, IL), and lane densitometry analyzed by standard 
procedures. 
2.10 Total and mitochondrial ROS production, membrane potential 
analysis and in vitro inhibition of metabolic enzyme activity  
Unfractionated EOC effusion cells were labelled with anti-CD44 and anti-CD117 antibodies. 
For total ROS evaluation, the DCFDA probe (1 μM; Invitrogen) was added for 30 min at 
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37°C; cells were then washed and mean fluorescence intensity (MFI) values were recorded. 
For mitochondrial ROS evaluation, H2-MitoTracker Red probe (H2-MTR, 20 nM; BD 
Bioscience) was added to the cells at 37°C for 15 min; to verify the specificity of the assay 
for ROS produced by the electron transport chain (ETC), we added pargyline, an inhibitor of 
mono-aminooxidases, which are an additional source of mitochondrial ROS [42]. H2O2 (100 
M) and Trolox (100 M; both from Sigma Aldrich) were used as positive and negative 
controls. The kinetics of mitochondrial ROS production was calculated using the ΔF/F0 
formula, where F0 is the fluorescent signal measured at time 0, and ΔF is the difference in 
MFI measured at the indicated time points minus the F0 value. Mitochondrial potential 
(Δψm) was measured by incubating the cells with TMRM (20 nM; Invitrogen) in the 
presence of cyclosporin A (1.6 M; Sigma Aldrich) for 20 min at 37°C. FCCP (100 nM; Sigma 
Aldrich) was used to induce depolarization; oligomycin (1 μM; Sigma Aldrich) and antimycin 
(1 M; Sigma Aldrich) were added to perturb membrane potential.  
To evaluate cell dependence on the ETC, fatty acid β-oxidation and the pentose phosphate 
pathway (PPP), 1 x 106 cells were plated in serum-free RPMI supplemented with oligomycin 
(1 μM), antimycin (1 μM), rotenone (1 μM), etomoxir (1 μM), DHEA (100 μM) or metformin 
(1 mM; all from Sigma Aldrich). Cell viability was evaluated with Annexin V/PI staining at 
different time points.  
2.11 Mitochondrial mass analysis 
To evaluate the mitochondrial mass, unfractionated EOC effusion cells were labelled with 
anti-CD44 and anti-CD117 antibodies, and incubated with the MitoTracker Green probe (0.1 
μM; Invitrogen) for 15 min at 37°C. Results were expressed as MFI. 
2.12 In vitro and in vivo 2-DG treatment 
For in vitro experiments, unfractionated EOC effusion cells were seeded in 6-well plates at 2 
x 105 cells/well, and treated with 6 g/L of 2-deoxiglucose (2-DG; Sigma Aldrich). At different 
time points (24, 48 and 72h), cytofluorimetric analysis was performed to evaluate 
CD44/CD117 co-expression and cell viability by AnnexinV/ PI staining. 
For in vivo experiments, after red blood cell lysis and lymphocyte removal, 5 x 105 
unfractionated EOC effusion cells were injected subcutaneously (s.c.) into seven-to-nine-
week-old Rag-2 γ-/- mice in 200 µl of Matrigel (BD Bioscience) in both dorsolateral flanks. 
When tumors reached 100 mm3 volume, mice were divided in two groups, one receiving i.p. 
three times/week 2 g/kg of 2-DG, the other a same volume of saline solution. Tumor growth 
was evaluated by caliper measurement; when tumors of the control group reached 600 mm3 
volume, the mice were sacrificed, tumors harvested by dissection, and isolated cells 
analyzed by FACS.  
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2.13 Oxygen consumption and Extracellular acidification rate 
The oxygen consumption rate (OCR) and Extracellular acidification rate (ECAR) were 
determined using the SeaHorse XF Extracellular Flux Analyzer (Seahorse Biosciences, San 
Jose, CA) [3, 4]. Briefly, 24-well plates (XF24 V7, Seahorse Biosciences) were coated with 20 
µl of Matrigel (Cultrex, Trevigen, Gaithersburg, MD) to allow cell adhesion to the bottom of 
the plates. Unfractioned EOC effusion cells and FACS-sorted populations were seeded at 3 x 
104 cells/well in complete RPMI medium, and incubated for 4 h at 37°C, 5% CO2. The XF 
assay was initiated by medium replacing with DME base supplemented with 10% FBS, 1% 
sodium pyruvate, 1% penicillin-streptomycin, 1% glucose (Sigma Aldrich) and 1% L-
glutamine. The cartridge of the instrument was loaded to dispense four different metabolic 
inhibitors at 20 min intervals: oligomycin (1 μM), followed by FCCP (0.6 μM for primary 
samples, 0.3 M for cell lines), antimycin (1 μM) and rotenone (1 μM; all from Sigma Aldrich) 
over 2 h. The assay was characterized by 3 sequential measurements of OCR and ECAR at 
time 0 and after each reagent addition thereafter. 
2.14 Confocal and fluorescence microscopy analysis 
For studying the kinetics of mitochondrial ROS production, FACS-sorted CD44+CD117+ and 
CD44+CD117- cells were maintained at 37°C in DMEM medium (Sigma Aldrich) 
supplemented with 10% FBS, 1% sodium pyruvate, and 1% Hepes (Lonza). Cultures were 
pretreated with 2 mM pargyline, and then labeled with 20 nM H2-MTR. ROS production was 
measured using an LSM510 confocal laser microscope (Zeiss, Jena, Germany) equipped with 
a 37°C, 5% CO2 incubator using Helium Neon (543 nm) and Argon (488 nm) lasers. Laser 
intensity, pinhole aperture, and photomultiplier parameters were standardized to allow 
comparison of signals obtained in different samples; images were recorded at 1 min 
intervals for 60 min. The mean fluorescent signal of H2-MTR in mitochondria of individual 
cells was quantitated with the Zeiss Histogram software tool, and expressed as ΔF/F0 as 
above. To evaluate MCT4 expression, FACS-sorted CD44+CD117+ and CD44+CD117- cells 
were stained with anti-MCT4 antibody (1:100; Santa Cruz Biotechnology); nuclei were 
stained with TOPRO3 (1:10,000; Invitrogen), and images recorded by confocal microscopy.  
2.15 CPI-613 treatment in vitro   
For in vitro experiments unfractionated EOC effusion cells were seeded in 6-well plates at 2 x 
105 cells/well, and treated with different concentrations (1, 5, 10, 25, 50, 100, 200 μM) of 
CPI-613 (Abcam). At different time points (24, 48, 72h), cytofluorimetric analysis was 
performed to evaluate CD44/CD117 co-expression and cell viability by AnnexinV/ PI staining. 
The analysis are compared to the control samples treated with DMSO, in which the drug is 
diluted, to check the toxicity of the reagent. 
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2.16 Statistical Analysis   
Data from replicate experiments were shown as mean values ± Standard Deviation [43]. 
Comparisons between groups were done by the two-tail Student’s t-test and Mann-
Whitney test, as appropriate. 
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3. RESULTS 
  
3.1 CD44+ CD117+ cells from ascitic effusions of epithelial ovarian cancer 
patients are characterized by a CSC phenotype 
 
Previous studies identified the co-expression of CD44 and CD117 as a marker of ovarian 
CSC [37]. Before investigating the metabolic profile of this subset, we tested whether 
these same markers identified CSC cells in ascitic effusions from EOC patients. As shown 
in Figures 13A and 13B, CD44+CD117+ cells accounted for a small percentage of the 
neoplastic population (2.5 ± 1.4%; range 0.2-5.0%). A similar percentage was found in EOC 
masses (Figure 13B), thus indicating that ascitic effusions mirror the composition of solid 
tumors. This percentage of CD44+CD117+ cells was also maintained after 
xenotransplantation of ascitic effusion cells into immunodeficient mice (Figure 13B).  
CD44+CD117+ cells displayed canonical hallmarks of CSC cells. EOC effusion cells formed 
spheroids when cultured in the absence of serum (Figure 13C), a phenomenon peculiar to 
CSC from different cancer histotypes. Spheroid formation was associated with a 
significant increase in the percentage of CD44+CD117+ cells and a reduction in the 
expression of the differentiation marker cytokeratin-7 (CK7) (Figure 13D), whereas culture 
in the presence of serum resulted in a significant increase in CK7 expression, and a 
decrease in the percentage of CD44+CD117+ cells (Figure 13D). Moreover, spheroid-
forming cells, as judged by ELDA, were enriched in the double-positive population (Figure 
13E). It is well-known that CSC present high tumor-initiating capacity. As shown in Table 
4, 7 out of 12 RAG-2γ-/- mice injected intra-peritoneally (i.p.) with 5 x 103 purified 
CD44+CD117+ cells developed tumors, whereas no tumors were observed in 10 mice 
injected with the same amount of  CD44+CD117- cells. Tumors could only be obtained 
when the number of inoculated CD44+CD117- cells was increased by 100-fold (Table 5).  
 
 
 
 
 
 
 
 
 
Table 5: CD44
+
CD117
+
 cells from EOC effusions show a higher tumorigenic potential. FACS-sorted 
CD44
+
CD117
+
 cells from EOC effusions show a higher tumorigenic potential, compared to the CD44
+
CD117
-
 subset, 
when injected into RAG-2y
-/- 
mice. 
 
 
 Cell number injected 
Cell type 5x103 5x104 5x105 
    
CD44+CD117+ 7/12 - - 
CD44+CD117- 0/10 0/1 5/5 
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When mice were injected subcutaneously (s.c.) with 1 x 105 cells, the tumors generated 
by CD44+CD117+ cells were far larger than those generated by the injection of 
CD44+CD117- cells (Figure 17F). 
We also compared the expression of several stemness-related genes and genes 
associated with epithelial-to-mesenchymal transition (EMT). In agreement with previous 
data, FACS-purified CD44+CD117+ cells displayed higher expression of all the stemness 
genes examined (Figure 17G), as well as of EMT-associated genes (Figure 17H). It is known 
that CSC are resistant to chemotherapy, in part due to the expression of drug-extruding 
pumps and detoxifying enzymes. Compared to single-positive cells, CD44+CD117+ cells 
displayed higher expression of MRP1, MRP2 and ABCG2 pumps, as well as of ALDH1A 
(Figure 17I), a detoxifying enzyme which is also considered as a canonical marker of CSC 
[30]. This observation was supported by the finding that the percentage of CD44+CD117+ 
cells increased dramatically following in vitro incubation of EOC effusion cells with 
Doxorubicin (Figure 17L). Altogether, these results indicate that the CD44+CD117+ cells 
represent a bona fide CSC population in EOC ascitic effusions. 
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Figure 17: CD44
+
CD117
+
 cells from ovarian cancer effusions show a phenotypic, molecular and functional 
profile compatible with a canonical CSC population. A. Cytofluorimetric analysis of a representative sample of 
ascitic effusion cells from an EOC–bearing patient. The expression of CD117 and CD44 was evaluated on CD45
neg
 cells, thus 
excluding contaminating CD45
+
 myeloid cells (middle panel).  B. Percentage of CD44+CD117+ cells in EOC ascitic effusions 
(n=45), solid EOC tumors (n=6), and primary xenografts derived from injection of EOC effusion cells into immunodeficient 
mice (n=12). The graph shows mean percentages ± SD.  C. Spheroid formation by EOC effusion cells cultured for 10 days in 
FBS-free RPMI enriched with EGF and bFGF (upper panels) followed by 10 days in complete RPMI to induce differentiation 
(lower panels). The results are representative of 5 experiments. D. FACS analysis of CD44/CD117 and CK7 expression in 
EOC effusion cells (Bulk), spheroids obtained after 10 days’ culture in the absence of FBS (Spheroids), and after 10 days of 
culture in differentiating conditions (Diff). The graph shows mean percentages of positive cells  SD measured in 10 
experiments. *p < 0.05. E. Spheroid-forming cell frequency, calculated by extreme limiting dilution analysis (ELDA) and 
expressed as the number of spheroid-forming cells/10
3
 cells. ELDA was performed on unsorted cells (bulk), and on FACS-
sorted CD44
+
CD117
+
 and CD44
+
CD117
-
 cells. Shown are mean spheroid-forming cell frequencies  SD calculated from 3 
consecutive experiments. *p < 0.05. F. Tumor generation in RAG-2γ-/- mice injected s.c. with 1 x 105 FACS-purified 
CD44
+
CD117
+
 cells (left) or CD44
+
CD117
-
 cells (right) from EOC ascitic effusions. G. qRT-PCR analysis of stemness-
associated genes in FACS-sorted CD44
+
CD117
+
 and CD44
+
CD117
-
 cells from EOC ascitic effusions. The relative expression of 
each mRNA in CD44
+
CD117
+
 cells compared to CD44
+
CD117
-
 cells was calculated as described in the Supplemental Data. 
Shown are mean values ± SD measured in ten samples. *p < 0.05. H. qRT-PCR analysis of genes coding for transcription 
factors involved in Epitelial-to-Mesenchymal Transition in FACS-sorted CD44
+
CD117
+
 and CD44
+
CD117
-
 cells from EOC 
effusion samples. Shown are mean relative expression values in CD44
+
CD117
+
 cells compared to CD44
+
CD117
-
 cells ± SD 
measured in ten samples. *p < 0.05. I. qRT-PCR analysis of the expression of multidrug resistance pumps and detoxifying 
enzymes in FACS-sorted CD44
+
CD117
+
 and CD44
+
CD117
-
 cells from EOC effusion samples. Shown are mean relative 
expression values in CD44
+
CD117
+
 cells compared to CD44
+
CD117
-
 cells ± SD measured in ten samples. *p < 0.05. L. Flow 
cytometry analysis of CD44/CD117 expression in EOC effusion cells incubated with different concentrations of Doxorubicin 
for 48 hr.   
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3.2  Ovarian CSC show a peculiar expression profile of glucose 
metabolism- and fatty acid β-oxidation associated enzymes 
 
We next compared the ex vivo metabolic profiles of FACS-purified CD44+CD117+ and 
CD44+CD117- cells by examining the expression of a panel of genes involved in key 
metabolic pathways, including glucose metabolism, the tricarboxylic acid (TCA) cycle, the 
electron transport chain (ETC), the pentose phosphate pathway (PPP), and fatty acid -
oxidation.  
Results of qRT-PCR revealed that the expression of the GLUT1 transporter was 
comparable in the two populations, whereas the levels of hexokinase II (HKII), 
phosphofructokinase (PFK) and total pyruvate kinase (PKM) were significantly higher in 
CD44+CD117+ cells (Figure 18A). Key TCA/ETC enzymes, such as citrate synthase (CS), 
isocitrate dehydrogenase (IDH2), and ATP5B, were also more highly expressed in the 
CD44+CD117+ subset (Figure 18A). To validate these findings, we investigated the protein 
levels of some of the above enzymes. It is known that GLUT1 exerts its glucose 
transporter function only when exposed on the outer cell membrane. Consistent with 
mRNA expression data, flow cytometry analysis of permeabilized cells indicated that the 
two subsets contained comparable total amounts of GLUT1  protein (Figure 18B, left 
panel). However, CD44+CD117+ cells expressed much higher levels of GLUT1 protein on 
the cell surface (Figure 18B, right panel). This finding was corroborated by analysis of 
fluorescent glucose uptake: CD44+CD117+ cells bound FITC-labelled glucose (2-NBDG) 
much more avidly, compared to CD44+CD117- cells (Figure 18C). Results of Western blots 
analysis (WB) verified that HKII and the TCA enzyme IDH2 were much more abundant in 
the CD44+CD117+ subset (Figure 18D).  
We also tested the expression of two enzymes involved in PPP, glucose-6-phosphate 
dehydrogenase (G6PD) and ribulose-5-phosphate isomerase (Ru5PI). The mRNAs coding 
for these enzymes were significantly more abundant in CD44+CD117+ cells (Figure 18E). 
This observation was confirmed at the protein level for G6PD (Figure 18F). Accordingly, 
incubation of ascitic effusion cells with dehydroepiandrosterone (DHEA), a known PPP 
inhibitor, resulted in a significant decrease in the viability of CD44+CD117+ cells, whereas 
no effect was observed in the CD44+CD117- subset (Figure 18G). 
An analysis of enzymes involved in the fatty acid -oxidation pathway, i.e. carnitine O-
acetyltransferase (CPT2), enoyl-CoA hydratase (ECHS1), acetyl-CoA acyl-transferase 1 
(ACAA1), ketoacyl-CoA thiolase 2 (ACAA2) and glycerol kinase, showed that all were 
more more expressed at the mRNA level in CD44+CD117+ cells, compared to the single-
positive counterpart (Figure 14H). The importance of this pathway in ovarian CSC was 
buttressed by an analysis of the effect of Etomoxir, an inhibitor of mitochondrial CPT1, 
which regulates the transport of long-chain fatty acids from the cytosol to mitochondria 
for -oxidation. After 6 hr incubation with Etomoxir, CD44+CD117+ cells displayed a 
significant reduction in viability (Figure 18I), whereas CD44+CD117- cells did not show any 
change, even after 24 hr of exposure to the drug. 
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Figure 18: CD44
+
CD117
+
 ovarian cancer cells show a different profile of glucose metabolism- and fatty acid 
β-oxidation-associated enzymes. A. FACS-sorted CD44+CD117+ and CD44+CD117- cells from EOC ascitic fluid samples 
were analysed by qRT-PCR for the expression of key enzymes of glucose metabolism, the tri-carboxylic acid (TCA) cycle 
and the electron transport chain (ETC). Shown are mean relative expression values in CD44
+
CD117
+
 cells compared to 
CD44
+
CD117
-
 cells ± SD measured in ten samples. *p < 0.05. B. Total and surface expression of the glucose transporter 
GLUT1 was evaluated by flow cytometry in permeabilized (left panel) and non-permeabilized (right panel) EOC effusion 
cells. One representative experiment out of five is shown.   C. Flow cytometry analysis of fluorescent glucose uptake by 
CD44
+
CD117
+
 and CD44
+
CD117
-
 cells from EOC ascitic effusions. The cells were labelled with anti-CD44 and anti-CD117 
antibodies, and 2-NBDG-FITC was added; fluorescence intensity was recorded after 1 min. One representative experiment 
out of eight is shown.  D. WB analysis of HKII and IDH2 expression in FACS-sorted CD44+CD117+ and CD44+CD117- cells 
from EOC effusions. Results in two representative samples are shown on the left; +/+ denotes CD44
+
CD117
+
 cells, and +/- 
indicates CD44
+
CD117
-
 cells. Signal intensities of the HKII and IDH2 bands were quantitated by scanning densitometry and 
normalized against the actin signal. Expression ratios were calculated by dividing normalized signal intensity values 
obtained for CD44
+
CD117
+ 
cells by those obtained for CD44
+
CD117
-
 cells. The graph shows mean expression ratios ± SD  
from three experiments. * p < 0.05. E. FACS-sorted CD44+CD117+ and CD44+CD117- cells from EOC ascitic fluid samples 
were analysed by qRT-PCR for the expression of some key enzymes of the Pentose Phosphate Pathway (PPP). Shown are 
mean relative expression values in CD44
+
CD117
+
 cells compared to CD44
+
CD117
-
 cells ± SD measured in ten samples. *p < 
0.05. F. WB analysis of G6PD expression in FACS-sorted CD44+CD117+ and CD44+CD117- cells from EOC ascitic effusions. 
Results obtained for two representative samples are shown on the left; +/+ and +/- denote CSC and non-CSC subsets, 
respectively. The ratio of G6PD expression in   CD44
+
CD117
+
 cells vs. CD44
+
CD117
-
 cells was calculated as described in the 
legend to Fig. 2D.  The graph shows the mean expression ratio ± SD calculated from three experiments. *p < 0.05. G. 
Unfractionated EOC effusion cells were incubated with the PPP inhibitor DHEA, and the viability of CD44
+
CD117
+
 and 
CD44
+
CD117
-
 cells was analysed at different times by Annexin V/PI staining. The graph shows mean cell viability ratios ± SD 
measured in three consecutive experiments (calculated as detailed in the Supplemental Data). *p < 0.05. H. FACS-sorted 
CD44
+
CD117
+
 and CD44
+
CD117
-
 cells from EOC effusion samples were analysed by qRT-PCR for the expression of some key 
enzymes of the fatty acid β-oxidation pathway. Shown are mean relative expression values in CD44
+
CD117
+
 cells 
compared to CD44
+
CD117
-
 cells ± SD measured in ten samples. *p < 0.05.  
I. Unfractionated EOC effusion cells were incubated with the fatty acid β-oxidation pathway inhibitor Etomoxir, and the 
viability of CD44
+
CD117
+
 and CD44
+
CD117
-
 cells analysed at different times by Annexin V/PI staining. The graph shows 
mean cell viability ratios ± SD calculated from three consecutive experiments *p < 0.05.  
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3.3  Ovarian Cancer Stem Cells overexpress key enzymes controlling the 
fuelling of pyruvate into the tricarboxylic acid cycle 
 
We next measured the expression levels of the key enzymes driving the commitment of 
pyruvate to the TCA cycle (Figure 19A). The ultimate destination of pyruvate to 
mitochondrial utilization is controlled by pyruvate dehydrogenase (PDH), whose activity 
is in turn regulated by PDH kinase (PDHK), which phosphorylates PDH, thus inactivating 
its function. Interestingly, while equal levels of total PDH were found by WB in the two 
subsets (Figure 19B), the levels of PDHK1 and of the inactive form of PDH (phospho-PDH) 
were significantly lower in CD44+CD117+ cells (Figure 19B). 
 
We tried to measure Oxygen consumption rate (OCR) and extracellular acidification rate, 
as index of the metabolism of cells, although we could not directly prove higher oxygen 
consumption and lower lactate production in CSC, as FACS sorting-associated stress 
precludes determining these functional parameters (Figure 20). The finding that 
CD44+CD117+ and CD44+CD117- cells express different amounts of PDHK1/phospho-PDH 
is a crucial clue indicating that ovarian CSC preferentially exploit the mitochondrial 
respiratory pathway compared to the non-CSC counterpart. 
 These data strongly suggest that pyruvate fuelling into the TCA cycle is privileged in 
CD44+CD117+ cells. Consistent with these findings, immunofluorescence analysis of ex 
vivo isolated EOC cells revealed significantly higher expression of the lactate transporter 
MCT4 in CD44+CD117- cells, compared to the CD44+CD117+ population (Figure 19C). This 
observation was confirmed by WB, which showed significantly lower levels of MCT4 in 
the CSC (Figure 19D). Altogether, these data suggest that pyruvate is preferentially 
conveyed to the TCA cycle in CD44+CD117+ cells, while the higher MCT4 expression found 
in the CD44+CD117- population is consistent with a more pronounced lactate flux and 
Warburg-like phenotype of this latter subset.  
A role for routing pyruvate into the TCA cycle has also been advanced for PKM, which 
exists in several isoforms, and regulates conversion of phosphoenolpyruvate to pyruvate. 
Results of qRT-PCR to compare the relative proportion of PKM1 and PKM2 between 
CD44+CD117+ and CD44+CD117- cells showed that the PKM2 isoform prevailed in both 
subsets, but we did not observe any difference in the expression of the two isoforms 
between CSC and the non-stem counterpart (Figure 21). 
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Figure 20: SeaHorse analysis of Oxygen Consumption Rate (OCR) and Extra-Cellular Acidification Rate (ECAR) 
in CSC-like and non-CSC-like cell subsets is heavily affected by FACS sorting procedures. A. Basal OCR in 
unsorted (bulk) and FACS-sorted CD44
+
CD117
-
 and CD44
+
CD117
+
 populations  from EOC effusion samples (left panel). Data 
are expressed as mean values  SD of ten different experiments. The OCR curves of bulk and sorted populations in a 
representative sample are shown in the right panel. The first three points of the graph indicate the basal OCR ratio. At 
different time points the following mitochondrial inhibitors were added: oligomycin (1 μM), FCCP (0.6 μM), rotenone (1 
μM) and antimycin (1M). *p <0.05. B. Basal ECAR in unsorted (bulk) and FACS-sorted CD44+CD117- and CD44+CD117+ 
populations  from EOC effusion samples (left panel). Data are expressed as mean values  SD of ten different experiments. 
The ECAR curves of bulk and sorted populations in a representative sample are shown in the right panel. The first three 
points of the graph indicate the basal ECAR ratio. At different time points the following mitochondrial inhibitors were 
added: oligomycin (1 μM), FCCP (0.6 μM), rotenone (1 μM) and antimycin (1M). *p <0.05. C. Representative flow 
cytometry analysis of CD44/CD117 co-expression in the ovarian cancer cell line IGROV-1.  D. OCR (left) and ECAR (right) 
curves of unsorted (bulk) and FACS-sorted CD44
+
CD117
-
 and CD44
+
CD117
+
 populations from the ovarian cancer cell line 
IGROV-1. The first three points of the graphs indicate the basal OCR and ECAR ratio. At different time points mitochondrial 
inhibitors were added as in A and B.  One representative sample out of four is shown. E. Representative flow cytometry 
analysis of CD44/CD117 co-expression in the ovarian cancer cell line OC316.  F. OCR (left) and ECAR (right) curves of 
unsorted (bulk) and FACS-sorted CD44
+
CD117
-
 and CD44
+
CD117
+
 populations from the ovarian cancer cell line OC316. The 
first three points of the graphs indicate the basal OCR and ECAR ratio. At different time points mitochondrial inhibitors were 
added as in A and B.  One representative sample out of four is shown.  
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Figure 19: The key enzymes driving glucose commitment to the TCA cycle are highly expressed in 
CD44
+
CD117
+
 ovarian cancer cells. A. In this schematic representation of the major steps of glucose metabolism, the 
PKM enzyme catalyses the conversion of phosphoenolpyruvate to pyruvate, but the key enzyme that drives its ultimate 
destination to oxidative metabolism is pyruvate dehydrogenase (PDH). The action of PDH is in turn regulated by PDHK, 
which phosphorylates PDH, thus inhibiting its function. TCA, tricarboxylic acid. B. WB analysis of phospho-PDH (pPDH), 
PDHK1, and total PDH expression in FACS-sorted CD44
+
CD117
+
 (+/+) and CD44
+
CD117
-
 (+/-) cells from EOC effusions. 
Results in two representative samples are shown on the left. Ratios of protein expression in CD44
+
CD117
+
 cells vs. 
CD44
+
CD117
-
 cells were calculated as described in the legend to Fig. 2D.  The graph shows mean expression ratios ± SD 
calculated from three experiments. *p < 0.05. C. FACS-sorted CD44+CD117+ and CD44+CD117- cells from EOC ascitic fluid 
samples were analysed by confocal immunofluorescence for the expression of the MCT4 lactate transporter. Nuclei were 
stained with TOPRO3. One representative experiment is shown on the left, and the histogram on the right shows mean 
values ± SD of MCT4 mean fluorescence intensity (MFI) from 10 different fields. *p < 0.05. D. CD44+CD117+ (+/+) and 
CD44
+
CD117
-
 (+/-) cells from EOC ascitic fluid samples were FACS-sorted and MCT4 expression analysed by WB. Results 
from four representative samples are shown on the left. The ratio of MCT4 expression in CD44
+
CD117
+
 cells vs. 
CD44
+
CD117
-
 cells was calculated as described in the legend to Fig. 2D. The graph shows the mean expression ratio ± SD 
calculated from six experiments. *p < 0.05.  
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Figure 21: The expression of the PKM1 and PKM2 isoforms does not differ between CD44
+
CD117
+
 and 
CD44
+
CD117
-
 ovarian cancer populations. FACS-sorted CD44+CD117+ and CD44+CD117- cells from EOC ascitic effusions 
were analyzed by qRT-PCR for the expression of total PKM and the PKM1 and PKM2 isoforms. The results were normalized 
to the housekeeping gene β2-microglobulin (as described in Supplemental Methods). For each cell subset, mRNA expression 
of PKM1 and PKM2 was expressed related to total PKM, which was defined equal to 1. Data are expressed as mean value ± 
SD of ten different experiments.  
 
 
 
 
3.4 Ovarian Cancer Stem Cells show higher mitochondrial activity and are 
more sensitive to inhibitors of the electron transport chain 
 
We thus addressed the respiratory activity of the two populations, starting with a 
comparison of total and mitochondrial reactive oxygen species (ROS) production in living 
EOC effusion cells labelled with anti-CD44 and anti-CD117 antibodies. Total ROS levels, 
measured by flow cytometry of cells incubated with the H2O2-sensitive fluorescent probe 
DCFDA, were significantly higher in the non-CSC population than in the CD44+CD117+ 
subset (Figure 23A). Mitochondrial ROS levels were measured using MitoTracker Red (H2-
MTR), a mitochondria-specific probe that is converted to fluorescent MTR upon oxidation 
by H2O2. Changes in H2-MTR fluorescence were measured using two approaches, (i) flow 
cytometry of unfractionated EOC cells following staining with anti-CD44/CD117 antibodies 
and (ii) in situ measurement by time-lapse laser scanning microscopy. Results showed that 
both the levels (Figure 23B) and rate of accumulation (Figure 23C) of mitochondrial ROS 
were significantly higher in the CD44+CD117+ than in the CD44+CD117- cells.  
To determine the metabolic status of the cells, independent of mitochondrial mass (Figure 
22), we investigated the effects of oligomycin on mitochondrial membrane potential (Δψm).  
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Figure 22: EOC CD44
+
CD117
+
 cells show higher mitochondrial mass. Mitochondrial mass in CD44+CD117- and 
CD44
+
CD117
+
 populations from EOC effusion cells was assessed by flow cytometry with the mitochondrial  probe 
MitoTracker Green. Data represent mean values ± SD of MFI ratios in five consecutive experiments. *p <0.05. 
 
 
 
This mitochondrial F1FO-ATP synthase inhibitor can be employed to discriminate whether 
the synthase is used to dissipate Δψm in order to produce ATP (as expected in cells using 
OXPHOS), or rather functions in a “reverse mode” to maintain Δψm at the expenses of ATP 
hydrolysis (as expected in cells diverting pyruvate from TCA cycle). Changes in Δψm were 
monitored using tetramethylrhodamine methyl-ester (TMRM), a fluorescent probe that 
accumulates in mitochondria in a Δψm-dependent manner. CD44
+CD117+ cells showed a 
significant hyperpolarization in response to oligomycin, thus demonstrating that in these 
cells the F1FO-ATP synthase works in a Δψm-dissipating “OXPHOS” mode (Figure 23D). In 
contrast, CD44+CD117- cells showed a significant depolarization in response to oligomycin, 
thus indicating a “reverse” mode of function of the F1FO-ATP synthase, which is strongly 
suggestive of a glycolytic, Warburg-like profile (Figure 23E). Upon addition of antimycin 
(which inhibits the Complex III of ETC), CD44+CD117+ cells showed a significant 
depolarization (Figure 23D), thus implying that the ETC was the main Δψm-generating 
pathway in these cells. On the contrary, antimycin did not alter Δψm in the CD44
+CD117- 
population (Figure 23E), consistent with poor ETC fuelling in these cells. Both cell subsets 
showed a comparable mitochondrial depolarization (Figure 23D-E) upon treatment with 
the control protonophore carbonylcyanide-p-trifluoromethoxyphenyl hydrazone (FCCP). 
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Figure 23:  Ovarian cancer CD44
+
CD117
+
 cells exhibit higher mitochondrial ROS production and an OXPHOS 
metabolic profile compared to CD44
+
CD117
-
 cells. A. Total ROS levels in unfractionated EOC effusion cells were 
measured by flow cytometry with the DCFDA probe following staining with anti-CD44 and anti-CD117 antibodies. 
Exogenous H2O2 and the ROS scavenger Trolox were used as positive and negative control, respectively. Mean 
Fluorescence Intensity (MFI) ratios were calculated dividing the MFIs measured for  CD44
+
CD117
+
 cells by those obtained 
for CD44
+
CD117
-
 cells.  The graph shows mean MFI ratios ± SD  from ten experimental repeats. *p < 0.05. B. Mitochondrial 
ROS levels in CD44- and CD117-labelled EOC effusion cells were measured using the H2-MTR probe. Changes in H2-MTR 
fluorescence were measured by flow cytometry after 20 minutes of incubation. H2-MTR ΔF/F0 values were calculated as 
described in the Methods. Mean values ± SD from twelve experiments are shown. *p < 0.05. C. Time-lapse laser scanning 
microscopy of mitochondrial ROS production in FACS-sorted CD44
+
CD117
-
 and CD44
+
CD117
+
 populations. Images obtained 
at 60 min in a representative experiment are shown on the left; the graph shows mean values ± SD of H2-MTR ΔF/F0 
recorded in at least 60 cells per time point per sample in 3 independent experiments. *p < 0.05. D, E. Mitochondrial 
membrane potential (Δψm) in CD44
+
CD117
+ 
(D) and CD44
+
CD117
-
 (E) cells was measured by flow cytometry with 
tetramethylrhodamine methyl ester (TMRM). FCCP was used as a control for the specificity of the probe, whereas 
antimycin and oligomycin were added to test the Δψm-generating mode of F1FO-ATP synthase. The graphs show mean 
values ± SD of TMRM MFI values in five experimental repeats. CD44
+
CD117
+
 cells showed a significant hyperpolarization in 
response to oligomycin, thus demonstrating the usage of the F1FO-ATP synthase in a Δψm-dissipating “OXPHOS” mode (D, 
right panel). In contrast, CD44
+
CD117
-
 cells showed a significant depolarization in response to oligomycin, thus 
demonstrating a “reverse” Δψm-generating mode of function of the F1FO-ATP synthase, which is strongly suggestive of a 
glycolytic metabolic profile (right panel in E). In both cell populations, mitochondria were rapidly and comparably 
depolarized in response to the control protonophore FCCP. *p < 0.05 compared to control (TMRM).  
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To corroborate these data, we compared the effects of the ETC inhibitors oligomycin, 
rotenone (an inhibitor of Complex I) and antimycin on the viability of the CD44+CD117+ and 
CD44+CD117- cells. Inhibition of oxidative phosphorylation had a dramatic effect on the 
survival of CD44+CD117+ cells, with a >50% decrease in viability after 6 hr treatment (Figure 
24A-C), whereas CD44+CD117- cells did not show any change in viability when cultured for 24 
hours in the presence of each inhibitor.  
A tentative model of the metabolic profile of CD44+CD117+ vs. CD44+CD117- EOC effusion 
cells that draws from these findings is proposed in Figure 24D.  
 
 
Figure 24: OXPHOS inhibitors significantly affect viability of CD44
+
CD117
+
 but not CD44
+
CD117
-
 ovarian 
cancer cells. A-C. Unfractionated EOC effusion cells were incubated in the absence or presence of oligomycin (A), 
antimycin (B) or rotenone (C), and the viability of CD44
+
CD117
+
 and CD44
+
CD117
-
 cells was analysed at different times by 
Annexin V/PI staining. Cell viability ratios were calculated as described in the Supplemental Data. Shown are mean values 
± SD from three consecutive experiments. *p < 0.05. D. Schematic model of the metabolic profile of CD44+CD117+ (CSC) 
and CD44
+
CD117
-
 (non-CSC) cells from EOC ascitic effusions. Left panel: bulk tumor cells present a glycolytic metabolic 
profile, in which most of the glucose entering the cells is converted to pyruvate, and eventually extruded as lactate by the 
MCT4 transporter. Right panel: in the CSC subset, a large proportion of the glucose entering the cell is converted to 
pyruvate to fuel the TCA cycle and ETC, which in turn increases mitochondrial ROS production. In these cells, a significant 
glucose fraction is shunted to PPP to potentiate the redox power of the cells (through NADPH and ROS scavenger 
generation). The thick arrows denote more active pathways, and the dotted arrows indicate non-preferential pathways. 
ETC, electron transport chain; PPP, pentose phosphate pathway; ROS, reactive oxygen species; TCA, tricarboxylic acid. 
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3.5 Ovarian Cancer Stem Cells resist in vitro and in vivo glucose 
deprivation, while maintaining their Cancer Stem Cell properties 
 
The finding of high glucose uptake and elevated PPP and OXPHOS activity in the CSC 
prompted us to investigate their response to glucose deprivation. This issue was  particularly 
compelling in view of data indicating that anti-angiogenic therapy causes glucose starvation 
in experimental tumors and it is associated with enhanced survival of CSC in patients. We 
thus cultured ascitic effusion cells in the presence and absence of glucose, and evaluated 
their phenotypic and functional profiles. Glucose starvation of EOC effusion cells was 
associated with a dramatic decrease in viability (Figure 25A, left panel), due to the 
preferential death of CD44+CD117- cells (not shown), and a significant enrichment in 
CD44+CD117+ cells (Figure 25A, right panel), conditions reverted by the re-addition of 
glucose (Figure S3).  
Cultivation of EOC effusion cells in the presence of 2-DG, a glucose analogue which prevents 
glucose accumulation via HKII blockade, resulted in a dramatic decrease in cell viability, 
while the percentage of CD44/CD117 co-expressing cells increased in parallel (Figure 18B). 
Administration of 2-DG to mice injected with ovarian cancer xenografts caused a conceivable 
reduction in the tumor growth rate (Figure 25C, left panel). Intriguingly, however, a 
significant enrichment in CD44+CD117+ cells was also found in tumors from 2-DG-treated 
animals, compared to controls (Figure 25C, right panel).  
 
Figure 25: Glucose starved CD44
+
CD117
+
 cells reconstitute the entire cell population after glucose re-
addition. A, B. Flow cytometry analysis of cell viability (A) and CD44/CD117 co-expression (B) of unfractionated EOC 
effusion cells cultured for 14 days in the presence (+Glu) or in the absence (-Glu) of glucose (Treatment) and after 10 days 
of glucose restoration (Recovery). Data are expressed as mean percent values ± SD of five different experiments. *p < 
0.05. 
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Nevertheless, glucose-starved cells fully maintained their original CSC properties. In fact, as 
judged by ELDA, culture in the absence of glucose was associated with a significantly higher 
ability to form spheroids, compared to cells kept under standard conditions (Figure 26D). 
Furthermore, 4/4 RAG-2 γ-/- mice injected i.p. with 1 x 103 cells previously cultured in the 
absence of glucose developed tumors, whereas no tumor formation was observed in 6 
animals injected with the same number of cells kept under normal culture conditions (not 
shown). In addition, tumors obtained by s.c. injection of 1 x 105 glucose-starved or non-
starved cells were much larger when glucose-starved cells were injected (Figure 26E). 
Altogether, these data indicate that glucose-starved CD44+CD117+ cells maintain the 
fundamental properties of CSC, and that glucose deprivation resistance is a consistent 
feature of the CD44+CD117+ subset in different in vitro and in vivo conditions.  
 
Figure 26: Ovarian cancer CD44
+
CD117
+
 cells resist in vitro and in vivo glucose deprivation, while 
maintaining their CSC properties. A. Unfractionated EOC ascitic effusion cells were cultured in the presence (+Glu) or 
absence (-Glu) of glucose for 14 days; cell viability (left panel) and the percentage of  CD44
+
CD117
+
 cells (right panel) were 
evaluated at different time points. Shown are mean values ± SD from ten consecutive experiments. *p < 0.05. B. Flow 
cytometry analysis of cell viability (upper panel) and CD44/CD117 co-expression (lower panel) of unfractionated EOC 
effusion cells cultured in the presence of the glucose analogue 2-DG. One representative experiment out of three is 
shown. C.  Six RAG-2 γ-/- mice were injected with 5 x 105 cells/flank from EOC effusion xenografts; when the tumors 
reached a volume of 100 mm
3
, 3 animals were treated with 2-DG, and 3 received saline as a control (CTRL). The left panel 
shows the kinetics of tumor growth, and the right panel reports the percentage of CD44
+
CD117
+
 cells in the resulting 
tumor masses. Data are mean values ± SD for six tumors/group. *p < 0.05 D. unfractionated EOC effusion cells were 
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cultured in the presence (+Glu) or absence (-Glu) of glucose. After 14 days the ability to generate spheroids was evaluated 
by ELDA. Shown are the mean values of spheroid-forming precursors/10
3
 cells ± SD in five consecutive experiments. *p < 
0.05. E. RAG-2 γ-/- mice were injected with 1 x 105 cells/flank from EOC effusion xenografts. Before inoculation, the cells 
were cultured for two weeks in standard medium (upper panel) or in medium without glucose (lower panel).  
 
 
3.6 Glucose deprivation modulates the metabolic profile of ovarian 
Cancer Stem Cells, while sparing their oxidative phosphorylation 
profile 
 
The relative increase in CD44+CD117+ cells in the absence of glucose was not due to their in 
vitro expansion or de novo co-expression of these receptors. In fact, the absolute number of 
input CD44+CD117+ cells did not significantly change over the glucose starvation period 
(Table 5). 
 
 
 CD44+CD117+ cell number in culture 
Sample no. day0 day14 (+ GLU) day14 (– GLU) 
PDOVCA #11 1950 2192 2346 
PDOVCA #12 2260 2199 2002 
PDOVCA #13 2000 2400 1472 
PDOVCA #14 2000 2788 2736 
PDOVCA #15 2400 2520 2560 
PDOVCA #17 2200 1740 1980 
PDOVCA #27 2346 2223 2488 
PDOVCA #29 1093 2270 1840 
PDOVCA #32 1375 1960 1364 
PDOVCA #39 2900 1219 1938 
    
mean 2052.4±514.8 2151.1±434.7 2072.6±456.2 
          P=0.88 ANOVA test 
Table 5: The absolute number of CD44
+
CD117
+
 cells is not affected by glucose starvation. The number of 
CD44/CD117 co-expressing cells in EOC effusions cultured for 14 days in the presence (+Glu) or absence (-Glu) of 
glucose was calculated from the percentage of CD44
+
CD117
+
 cells obtained by flow cytometry analysis  of 2x10
5
 
cells/culture condition. 
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Moreover, when ascitic effusion cells were labelled with PKH26, a fluorescent dye used to 
monitor cell division, mostly PKHhigh cells were found after glucose deprivation, whereas in 
normal culture conditions several peaks of PKH intensity were observed, reflecting serial 
dilution of the dye due to cell replication (Figure 27A). These findings indicated that 
CD44+CD117+ cells did not undergo proliferation, but remained quiescent when cultured in 
the absence of glucose. This observation was corroborated by qRT-PCR analysis of cyclin D, E, 
and B expression, which was strongly down-modulated in glucose-starved cells (Figure 27B). 
Interestingly, expression of the pro-apoptotic genes BAX and BAD was also significantly 
reduced in glucose-starved CD44+CD117+ cells, whereas no change in expression of the anti-
apoptotic genes BCL-2 and BCL-X was observed (Figure 27B).  
Glucose-starved CD44+CD117+ cells showed an overall down-regulation in expression of 
glucose metabolism-related genes, as well as in genes involved in fatty acid -oxidation, 
compared to cells cultured in the presence of glucose (Figure 27C). However, GLUT1 was 
expectedly up-regulated by glucose deprivation (Figure 27C); interestingly, the TCA/ETC 
genes CS, IDH2 and ATP5B did not change significantly following culture in the absence of 
glucose (Figure 27C). Accordingly, the response of mitochondrial Δψm to oligomycin showed 
a comparable OXPHOS profile in freshly isolated (see Figure 23D) and glucose-starved 
CD44+CD117+ cells (Figure 27D). Thus, it is reasonable to conclude that ovarian CSC resist 
glucose starvation by entering a quiescent state, while maintaining their preferential 
OXPHOS profile. It is possible that ovarian CSC could resist glucose deprivation thanks to the 
exploitation of anaplerotic pathways such as glutaminolysis to support ATP production. To 
test this hypothesis, we cultured unfractionated EOC cells under glucose deprivation for 14 
days, followed by an additional L-glutamine and/or sodium pyruvate starvation for 72 hr. As 
shown in Figure 7E, L-glutamine deprivation of glucose-starved CD44+CD117+ cells caused a 
>50% decrease in cell viability, while withdrawal of both L-glutamine and sodium pyruvate 
caused death of virtually all the cells (Figure 27E).  
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Figure 27: Glucose deprivation modulates the metabolic profile of ovarian cancer CD44
+
CD117
+
 cells, while 
sparing their OXPHOS profile. A. Unfractionated EOC effusion cells were labelled with PKH26, and maintained in 
culture in the presence (+Glu) or absence (-Glu) of glucose. PKH26 staining was evaluated in the two culture conditions 14 
days later, and analysed by FlowJo to monitor cell division. One representative experiment out of four is shown. B. 
Unfractionated EOC effusion cells were cultured in the presence (+Glu) or absence (-Glu) of glucose, and the expression of 
cyclins and apoptosis-associated genes was evaluated by qRT-PCR 14 days later in FACS-sorted CD44
+
CD117
+
 cells. The 
relative expression of each mRNA in glucose-starved CD44
+
CD117
+
 cells compared to control CD44
+
CD117
+
 cells was  
calculated as described in the Supplemental Data. Mean values ± SD from six samples are shown. *p < 0.05. C. The 
expression of a panel of metabolism-associated genes was evaluated in CD44
+
CD117
+
 cells cultured as described in B. 
Relative mRNA expression values were calculated as described above. Shown are mean values ± SD from six samples. *p < 
0.05. D. Mitochondrial membrane potential (Δψm) was measured by flow cytometry as detailed in Figure 4D-E in 
CD44
+
CD117
+ 
cells previously cultured for 14 days in the absence of glucose.  Antimycin and oligomycin were added to test 
the Δψm-generating mode of F1FO-ATP synthase. Glucose-starved CD44
+
CD117
+
 cells showed a profile fully comparable to 
that of non-starved CSC (see Figure 4D), with a significant hyperpolarization in response to oligomycin, demonstrating that 
glucose deprivation did not change the Δψm-dissipating “OXPHOS” mode of the F1FO-ATP synthase. Shown are mean 
TMRM MFI values ± SD from three experiments. *p < 0.05 compared to control.  E. Unfractionated EOC effusion cells were 
cultured for 14 days in the absence of glucose, and then transferred to media with/without glucose, L-glutamine and 
sodium pyruvate, as specified on the abscissa. Cell viability was analysed by Annexin V/PI staining 72 h later. Shown are 
mean percentages of live cells (Annexin V
neg
/PI
neg
) ± SD from three experiments. *p < 0.05. 
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3.7  Metformin and CPI-613, innovative drug targeting metabolism 
 
In conclusion in this study we show that a subpopulation of CD44+CD117+ EOC cells fulfilling 
the canonical properties of CSC does not preferentially exploit a glycolytic metabolism, 
privileging instead the mitochondrial respiratory pathway. These observation may be a 
possible target of novel treatment strategies against CSC population. 
Regarding these premises, the most innovative drugs used to target mitochondria functions 
are: Metformin and CPI-613.  
 
Metformin, which also inhibits mitochondrial Complex 1 (like rotenone) and is now in the 
spotlight as a promising anticancer drug, had a dramatic effect on the survival of 
CD44+CD117+ cells, with a >50% decrease in viability after 48 hr treatment (Figure 28), 
whereas CD44+CD117- cells did not show any change in viability when cultured for 72 hours 
in the presence of each inhibitor.  
 
Moreover, in accordance with an anti-Complex I effect, the mitochondrial membrane 
potential of CD44+CD117+ cells was dramatically reduced following 90 min incubation with 
metformin (Figure 29), and, as expected, the addition of oligomycin did not increase Δψm, a 
response that was instead evident in the control population.  
 
 
Figure 28: Effect of metformin in CD44
+
CD117
+
 cell viability.  Unfractionated EOC effusion cells were 
incubated in the absence or presence of metformin (1 mM) and cell viability evaluated in CD44
+
CD117
+
 and 
CD44
+
CD117
-
 cells at various time intervals. Cell viability ratios were calculated at different time points (24, 
48, 72h), by AnnexinV/ PI staining, with results expressed as mean values ± SD from three consecutive 
experiments. *p < 0.05.  
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Figure 29: Effect of metformin on ETC inhibition. To validate the effect of metformin on ETC, mitochondrial 
membrane potential (Δψm) was measured by flow cytometry with the TMRM probe in CD44
+
CD117
+ 
cells from 
EOC effusions, either untreated (ctrl) or after 90 min of treatment with 1 mM metformin. Oligomycin was 
added to test the Δψm-generating mode of F1FO-ATP synthase. Shown are mean MFI values ± SD from five 
experimental repeats. *p < 0.05. 
Very interesting preliminary results were also obtained with treatment with CPI-613 (Figure 30), 
specific inhibitor of two key enzymes of TCA cycle: PDH and α-KGH. As a matter of fact, treatment, 
for 24 hours with different concentration of CPI-613 (1ug -200ug), showed a >80% decrease of 
CD44/CD117 expression in cell lines IGROV-1 and OC316, in example of primary samples and 
xenograft. This is a demonstration of the effectiveness of this drug in the target treatment of CD44 + 
CD117+ cell population. 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Effect of CPI-613 in CD44
+
CD117
+
 cell viability. Unfractionated EOC effusion cells were incubated in 
the absence or presence of CPI-613 (different concentrations) and cell viability evaluated in CD44
+
CD117
+
 and 
CD44
+
CD117
-
 cells at various time intervals. Cell viability ratios were calculated by AnnexinV/ PI staining. 
(black: DMSO ,  green: CPI-613). 
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4. DISCUSSION AND CONCLUSIONS 
In this study we investigated the metabolic profile of CSC obtained ex vivo from ascitic 
effusions of EOC-bearing patients. In particular, we addressed our interest to ovarian cancer 
in view of several considerations:  
-  ovarian cancer is a very malignant neoplasm, due to late diagnosis and its chemo 
resistance; 
-  ovarian cancer cells can be obtained in a relatively easy manner, by taking advantage 
of their preferential growth as ascitic effusions;  
- unlike other types of cancer, where the debate on the markers characterizing CSC is 
largely open, a body of evidence indicates that ovarian CSC co-express CD44 and 
CD117,  which may help in following the relative enrichment in these cells during the 
experimental procedures.  
The research field of the CSC has been very successful in recent years, considering their 
property of being “the guilty cells” for maintaining tumor growth and thus for their possible 
involvement in the improvement of the therapies. Unfortunately, many aspects of their 
biology are still misunderstood and then the chances of finding therapies targeting these 
cells are as yet elusive. In particular CSC biology is intricate [14], and the CSC phenotype may 
encompass a gradient, where tumor progenitors at different stemness levels are comprised 
under the umbrella of “stem” marker expression [78]. One of the most important difficulty is 
the lack of a universal marker; each tumor is characterized by its own marker, able to 
recognize the CSC population in different percentages. Moreover, CSC are able, like normal 
stem cells, to produce a progenitor cell populations, which later form the differentiated cells. 
Hence, it is difficult to identify the “true” stem (“ the mother of all other cells”); indeed the 
complexity of the tumor is also characterized by  the heterogeneity of the cancer stem cells. 
 Nonetheless, our data point to the ovarian CD44+CD117+ subset as a bona fide CSC 
population, which clearly differs molecularly and functionally from the bulk of differentiated 
tumor cells.  
In fact the CD44+CD117+ cells: 
 Are isolated through the expression of two known stem markers: CD44 and CD117; 
 Are characterized by an over-expression of genes associated to stem-cell pathway 
(Nanog, Sox2, Oct4), of genes encoding pumps and detoxifying enzymes, involved in 
drug-resistance, and genes encoding enzymes involved in the process of epithelial-
mesenchimal transition; 
 Are able to form spheroids under particular cell culture conditions and present high 
tumorigenicity in vivo in immunodeficient mice. 
Based on these premises, the innovative area of interest of our project is the metabolic 
characterization of these cells, isolated by primary samples. We have demonstrated that: 
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 ovarian CD44+CD117+ cells overexpress key genes associated with glucose 
uptake, ETC/TCA, PPP, and fatty acid -oxidation;  
 CD44+CD117+ cells have lower levels of PDHK1 and phospho-PDH than 
CD44+CD117- cells, indicating their propensity to direct pyruvate utilization 
towards the Krebs cycle; 
 CD44+CD117+ cells produce higher levels of mitochondrial ROS, and die when the 
mitochondrial respiratory chain is blocked. Moreover, a clear-cut qualitative 
difference in response to inhibition of the F1F0-ATP synthase by oligomycin 
demonstrates that in CD44+CD117+ cells this enzyme is used to dissipate Δψm in 
order to produce ATP, whereas in CD44+CD117- cells it functions in a “reverse 
mode” to maintain Δψm at the expenses of ATP hydrolysis.  
Although we could not directly prove higher oxygen consumption and lower lactate 
production in CSC, as FACS sorting-associated stress precludes determining these functional 
parameters, the finding that CD44+CD117+ and CD44+CD117- cells express different amounts 
of PDHK1/phospho-PDH is a crucial clue indicating that ovarian CSC preferentially exploit the 
mitochondrial respiratory pathway compared to the non-CSC counterpart.  
Furthermore, it has been reported that the balance between the PKM1 and PKM2 isoforms 
of PKM may be critical in directing pyruvate to either lactate production or mitochondrial 
utilization [75, 76]. Indeed, in models of enforced expression or silencing of these enzymes in 
malignant cell lines, PKM2 expression is associated with the Warburg effect [62, 77]. 
Although we observed a significant elevation in total PKM expression in the CSC subset, we 
did not observe any difference in the relative proportion of PKM1 and PKM2 expression 
between CD44+CD117+ and CD44+CD117- cells. However, molecular and biochemical data on 
PKM2 may be misleading and may not reflect its actual enzymatic activity, as PKM2 function 
depends on the formation of dimers/tetramers [77], whose detection is possible under 
controlled conditions in established cell lines, but unfeasible in our setting.  
Our data clearly indicate that EOC CD44+CD117+ cells are much less dependent on glucose 
than the CD44+CD117- population. This finding is in line with recent observations on in vitro 
resistance of glioblastoma CSC to glucose deprivation [78]. Intriguingly, although the 
metabolic profile of their CD133+ population was not characterized, these investigators 
observed pronounced expression of the glucose transporter GLUT3. Our finding of strong 
surface expression of GLUT1 in ovarian CSC leads us to ask why these relatively quiescent 
OXPHOS-driven cells should manifest high glucose avidity compared to the bulk tumor cells, 
and how limiting the Warburg effect might be advantageous to ovarian CSC. We found that 
ovarian CSC are characterized by high PPP activity, a finding consistent with their high 
glucose uptake and HKII expression. One key function of the PPP is to maintain high levels of 
NADPH, which in turn is essential for recharging ROS-scavenging enzymes. Thus, the finding 
of higher PPP activity, along with high OXPHOS and mitochondrial ROS production, might 
point to differences in ROS homeostasis between CSC and the bulk tumor cell population, in 
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order to preserve the integrity of the former, and avoid further DNA damage or irreversible 
opening of mitochondrial pores. In addition, the higher expression of fatty acid -oxidation 
enzymes by CD44+CD117+ cells could indicate that these metabolites also play an important 
role within the CSC energy economy, probably to produce intermediates for the Krebs cycle. 
In this regard, intriguing results obtained in a different setting have shown that inhibition of 
fatty acid -oxidation by Etomoxir/Orlistat is associated with selective pro-apoptotic effects 
in human acute myeloid leukemia progenitors [79].  
The metabolic profile and glucose deprivation resistance of ovarian CSC could also help in 
explaining the refractoriness of EOC to therapies restricting oxygen and nutrient supply. 
Studies of experimental tumors [80]  and human cancer [81, 82,] showed that anti-
angiogenic therapies are associated with an increase in the percentage of CSC in the residual 
tumor mass; indeed, our data on the effect of in vivo 2-DG treatment on tumor generation 
further reinforce this idea. We observed that CSC undergo complete quiescence in the 
absence of glucose, and down-regulate most metabolic activities, while maintaining an 
OXPHOS profile; this phenomenon could be instrumental in helping CSC to escape damage in 
hypo-oxygenated tumor areas, but the mechanisms determining this phenotype are unclear. 
In this regard, the observed activity of metformin on CD44+CD117+ cells, which confirms and 
extends previously reported effects on pancreatic CSC, deserves further investigation, and 
suggests that approaches combining anti-angiogenic drugs and metformin could be effective 
for eradicating CSC. 
 
The CD44+CD117+ cells are characterized by a different metabolism compared to the non-
stem counterpart. The possible reason of this metabolic shift could be the possibilities of the 
CSC to produce more energy in ATP than the tumor cells (36 ATP molecules in mitochondrial 
metabolism instead of 4 ATP molecules in Warburg-exploiting cells) through a single 
metabolic cycle. Moreover, many other metabolic pathways are involved in the synthesis of 
metabolites useful to the Krebs cycle; they guarantee the synthesis of proteins, nucleotides 
and fatty acids and allow the survival of the CSC. In fact we have demonstrated that the 
CD44+CD117+ cells resist the glucose deprivation through the glutamine pathway, as glucose 
and glutamine starvation induce the death of these cells. Moreover, treatment with CP-613, 
which also targets the key enzyme α-KGH, showed similar results. 
In this regard, we have introduced an innovative drug in our project, actually in clinical trials, 
the CPI-613, which targets two specific enzymes of the mitochondrial TCA cycle. The finding 
that treatment with this drug induce a selective death of the CSC has further confirmed our 
findings of a different metabolism between CSC and non-CSC. Currently, we have only 
preliminary results of an in vitro treatment but it is possible start of a new field of research, 
studying a possible combination with classical chemotherapy and the drug toxicity in vivo. 
Unfortunately, we have no feedback from clinical trials, as they will end their assessment in 
2018.  
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The finding of a different metabolism in CSC and the good results of the CPI-613 treatments 
could be a possible therapeutic application, able to eradicate completely the CSC and to stop 
the phenomenon of aggressive recurrence, typical of ovarian cancer after the first cycle of 
therapy. 
 
5. FUTURE PERSPECTIVES 
This project opens new avenues of investigation, as in literature, little is known about the 
metabolism of CSC. 
 
First of all, it is interesting to confirm the results obtained with the CPI-613 treatment and 
organize experimental tests in vivo in a mouse model. Really interesting could be the 
combination of CPI-613 with classical chemotherapy (Doxorubicin, Paclitaxel, 
Carboplatinum) or with drugs that target cancer metabolism (2DG, Etomoxir, DHEA, 
Metformine). 
Nevertheless, it is necessary to understand the strategies of the CSC to survive in specific 
stress conditions. Regarding the nutrient deprivation, it is in program to continue the 
analysis of metabolic strategies, that permit to the CSC to survive and to stay in a quiescent 
state, as we have demonstrated in our experiments of glucose deprivation. The possibilities 
could be the glutamine metabolism; Lobo and colleagues have demonstrated that 
glutaminolysis is another main pillar for energy production. High extracellular glutamine 
concentrations stimulate tumor growth and are essential for cell transformation [88] and for 
this reason CPI-613, which targets the enzyme α-KGH, could be a suitable option for cancer 
cells and for CSC. On the other hand, gluconeogenesis in cancer stem cells could be a field of 
interest. It is a metabolic pathway that results in the generation of glucose from non-
carbohydrate carbon substrates such as pyruvate, lactate, glycerol, and glucogenic amino 
acids. It is one of the two main mechanisms used by humans and many other mammals to 
maintain blood glucose levels, avoiding low blood glucose level (hypoglycemia), necessary 
during a period of nutrient starvation. The other means of maintaining blood glucose levels 
is through the degradation of glycogen (glycogenolysis) (Figure 31).  
At the end, it will be mandatory to investigate the phenomenon of autophagy in CSC. The 
modulation of autophagy is now recognized as one of the hallmarks of cancer cells. 
Depending on the context and the type of cancer, autophagy may suppress tumor growth or 
may allow cancer cells to overcome metabolic stress and the cytotoxicity of chemotherapy. 
Recent studies have shed light on the role of autophagy in normal stem cells and in cancer 
stem cells (CSC) [83, 84]. 
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Figure 31: Metabolic strategies for the survival of cancer cells in nutrient starvation. Critcal care medicine. 
Section 5, chapter 74 “Nutritional aspects” 
 
 
 
Moreover, current cancer therapies including chemotherapy and ionizing radiation are 
known to induce autophagy within tumor cells. However, autophagy plays a dual role of  
either pro-cell survival or pro-cell death in response to these cancer treatments, depending 
on the cellular context and the nature of the treatment. It could be of interest to correlate 
between autophagy and metabolism, as the metabolic demand of cancer cells is higher than 
that of normal cells, and autophagy may help overcome cellular energy deficits (Figure 32) 
[85]. Furthermore, in a subset of these cancer cells, downregulation of critical autophagy 
proteins abolishes their tumorigenicity and reduces glucose metabolism indicating the high 
dependence on autophagy for their survival [86]. Concerning these considerations, 
autophagy could be a suitable target, as it permits the survival of CSC in stress conditions. 
However, it remains to be determined how autophagy contributes to the metabolic shift of 
CSC. 
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Figure 32: Autophagy induction in specific metabolic stress, like oxygen starvation. Bassam Janji, Elodie Viry, 
Joanna Baginska, Kris Van Moer and Guy Berchem. Role of Autophagy in Cancer and Tumor Progression. 
 
 
 
 
 
 
 
 
 
 
Thus, understanding of pathway biochemistry in cancer cells will help to determine the best 
targets for possible intervention. Nevertheless, the finding that there is a difference 
between the metabolism of cancer cells and CSC, and the ability of CSC to survive in specific 
stress conditions, open an interesting research field, to find particular therapeutic targets, 
shown in the following pictures as strategic points to hit (Figure 33, pink circle).  
Ultimately, these efforts will determine whether a sufficient therapeutic window exists to 
spare normal tissues from unwanted toxicity and whether further investigation of the 
anticancer potential of agents that target these enzymes is warranted. 
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Figure 33: Targeting metabolic enzymes like new hallmarks of cancer. Matthew G. Vander Heiden. Targeting 
cancer metabolism: a therapeutic window opens. Nature Reviews. 2011; 10:671-684. 
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